[
  {
    "slug": "17a-methyl-1-testosterone",
    "title": "17a-Methyl-1-testosterone",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "17a-Methyl-1-testosterone guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "17a-Methyl-1-testosterone belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "17a-Methyl-1-testosterone requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for 17a-Methyl-1-testosterone and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact 17a-Methyl-1-testosterone timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "17a-Methyl-1-testosterone may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is 17a-Methyl-1-testosterone appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "17a-Methyl-1-testosterone: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=17a-Methyl-1-testosterone",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "17a-Methyl-1-testosterone: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=17a-Methyl-1-testosterone",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "17a-Methyl-1-testosterone: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "17a-Methyl-1-testosterone",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "5-amino-1mq",
    "title": "5-amino-1mq",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "5-amino-1mq guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "5-amino-1mq belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "5-amino-1mq should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for 5-amino-1mq and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log 5-amino-1mq timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "5-amino-1mq may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for 5-amino-1mq versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "5-amino-1mq: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=5-amino-1mq",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "5-amino-1mq: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=5-amino-1mq",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "5-amino-1mq: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "5-amino-1mq",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "ace-031",
    "title": "ACE-031",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "ACE-031 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "ACE-031 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "ACE-031 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for ACE-031 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log ACE-031 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "ACE-031 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for ACE-031 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "ACE-031: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=ACE-031",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "ACE-031: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=ACE-031",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "ACE-031: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "ACE-031",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "adamax",
    "title": "Adamax",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Adamax guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Adamax should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For Adamax, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Adamax and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Adamax timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Adamax may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Adamax versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Adamax: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Adamax",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Adamax: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Adamax",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Adamax: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Adamax",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "adipotide",
    "title": "Adipotide",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Adipotide guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Adipotide belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "Adipotide should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Adipotide and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Adipotide timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Adipotide may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Adipotide versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Adipotide: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Adipotide",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Adipotide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Adipotide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Adipotide: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Adipotide",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "ahk-cu",
    "title": "AHK-CU",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "AHK-CU guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "AHK-CU should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For AHK-CU, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for AHK-CU and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log AHK-CU timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "AHK-CU may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for AHK-CU versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "AHK-CU: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=AHK-CU",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "AHK-CU: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=AHK-CU",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "AHK-CU: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "AHK-CU",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "aicar",
    "title": "Aicar",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Aicar guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Aicar should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For Aicar, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Aicar and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Aicar timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Aicar may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Aicar versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Aicar: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Aicar",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Aicar: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Aicar",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Aicar: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Aicar",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "alprostadil",
    "title": "Alprostadil",
    "aliases": [],
    "category": "Research Peptide",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Alprostadil guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Alprostadil is easier to judge when your notes read like a timeline instead of scattered snapshots. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "Alprostadil protocols are easier to interpret when you avoid changing multiple variables at once. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Alprostadil and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Alprostadil timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Alprostadil versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Alprostadil: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Alprostadil",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Alprostadil: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Alprostadil",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Alprostadil: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Alprostadil",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "coach"
  },
  {
    "slug": "anadrol",
    "title": "ANADROL",
    "aliases": [
      "ANADROL(Oxymetholone)"
    ],
    "category": "Oral Compound",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "ANADROL guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "ANADROL tracking is most useful when you link dose timing, tolerance, and symptom context in one log entry. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "ANADROL decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for ANADROL and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact ANADROL timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is ANADROL appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "ANADROL: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=ANADROL",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "ANADROL: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=ANADROL",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "ANADROL: MedlinePlus safety and interaction context",
        "url": "https://medlineplus.gov/?query=ANADROL",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "ANADROL",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound",
        "Supportive"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "anavar",
    "title": "ANAVAR",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "ANAVAR guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For ANAVAR, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "ANAVAR should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for ANAVAR and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact ANAVAR timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "ANAVAR may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is ANAVAR appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "ANAVAR: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=ANAVAR",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "ANAVAR: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=ANAVAR",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "ANAVAR: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "ANAVAR",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "andarine-s4",
    "title": "Andarine S4",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Andarine S4 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Andarine S4, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Andarine S4 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Andarine S4 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Andarine S4 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Andarine S4 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Andarine S4 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Andarine S4: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Andarine%20S4",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Andarine S4: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Andarine%20S4",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Andarine S4: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Andarine S4",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "androxal-enclomiphene",
    "title": "Androxal(Enclomiphene)",
    "aliases": [
      "Androxal(Enclomiphene)"
    ],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Androxal(Enclomiphene) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Androxal, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For Androxal, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Androxal and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Androxal timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Androxal may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Androxal appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Androxal(Enclomiphene): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Androxal",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Androxal(Enclomiphene): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Androxal",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Androxal(Enclomiphene): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Androxal",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "aod-9604",
    "title": "AOD-9604",
    "aliases": [
      "HGH Fragment",
      "AOD9604"
    ],
    "category": "Fat Loss Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "AOD-9604 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "AOD-9604 conversations can drift into easy cut promises. The better approach is tight logging, stable baseline habits, and honest separation of signal from routine variability.",
    "dosingSection": {
      "overview": "For AOD-9604, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for AOD-9604 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log AOD-9604 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "AOD-9604 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for AOD-9604 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "AOD-9604: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=AOD-9604",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "AOD-9604: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=AOD-9604",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "AOD-9604: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=AOD-9604",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "AOD-9604: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=AOD-9604+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "AOD-9604",
    "subtitle": "AOD-9604 practical guide for conservative protocol interpretation.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "ara-290",
    "title": "ARA-290",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "ARA-290 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "ARA-290 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For ARA-290, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for ARA-290 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log ARA-290 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "ARA-290 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for ARA-290 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "ARA-290: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=ARA-290",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "ARA-290: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=ARA-290",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "ARA-290: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "ARA-290",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "arimidex",
    "title": "ARIMIDEX",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "ARIMIDEX guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "ARIMIDEX tracking improves fast once you define one clear objective and log against it every week. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "With ARIMIDEX, consistency beats complexity. Hold one clean routine long enough to produce signal. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for ARIMIDEX and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact ARIMIDEX timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is ARIMIDEX appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "ARIMIDEX: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=ARIMIDEX",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "ARIMIDEX: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=ARIMIDEX",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "ARIMIDEX: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "ARIMIDEX",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach"
  },
  {
    "slug": "aromasin-exemestane",
    "title": "Aromasin(Exemestane)",
    "aliases": [
      "Aromasin(Exemestane)"
    ],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Aromasin(Exemestane) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Aromasin is easier to judge when your notes read like a timeline instead of scattered snapshots. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Aromasin protocols are easier to interpret when you avoid changing multiple variables at once. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Aromasin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Aromasin timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Aromasin appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Aromasin(Exemestane): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Aromasin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Aromasin(Exemestane): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Aromasin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Aromasin(Exemestane): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Aromasin",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach"
  },
  {
    "slug": "b12",
    "title": "Vitamin B12",
    "aliases": [
      "Cyanocobalamin",
      "Methylcobalamin",
      "B12"
    ],
    "category": "Vitamin",
    "status": "nutrient",
    "statusLabel": "Nutrient Support",
    "metaDescription": "Vitamin B12 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "B12 support works best when form, timing, and symptom context are tracked together. This page helps you avoid generic energy felt better logs.",
    "dosingSection": {
      "overview": "For Vitamin B12, conservative adjustments and measured rechecks are safer than abrupt protocol jumps. [C1]",
      "protocolPatterns": [
        "Keep Vitamin B12 schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Vitamin B12 timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Vitamin B12, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Vitamin B12: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Vitamin%20B12&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Vitamin B12: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Vitamin%20B12",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Vitamin B12: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Vitamin%20B12",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Vitamin B12: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Vitamin%20B12+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Vitamin B12",
    "subtitle": "Vitamin B12 support guide with form and symptom-context notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Vitamin",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "bac-water",
    "title": "BAC Water",
    "aliases": [],
    "category": "Research Peptide",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "BAC Water guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "BAC Water works best as a steady support protocol with measured check-ins rather than short reactive cycles. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "BAC Water decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for BAC Water and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log BAC Water timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for BAC Water versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BAC Water: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BAC%20Water",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BAC Water: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BAC%20Water",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BAC Water: MedlinePlus safety and interaction context",
        "url": "https://medlineplus.gov/?query=BAC%20Water",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "BAC Water",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound",
        "Supportive"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "support"
  },
  {
    "slug": "bam15",
    "title": "BAM15",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "BAM15 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For BAM15, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "BAM15 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for BAM15 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact BAM15 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "BAM15 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is BAM15 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BAM15: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BAM15",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BAM15: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BAM15",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BAM15: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "BAM15",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "bc-boldenone-cyp",
    "title": "BC(Boldenone Cyp)",
    "aliases": [
      "BC(Boldenone Cyp)"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "BC(Boldenone Cyp) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "BC should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "BC requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for BC and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact BC timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "BC may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is BC appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BC(Boldenone Cyp): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BC",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BC(Boldenone Cyp): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BC",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BC(Boldenone Cyp): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "BC",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "beinaglutide",
    "title": "Beinaglutide",
    "aliases": [
      "Benaglutide",
      "Beisu"
    ],
    "category": "GLP-1",
    "status": "regional-approval",
    "statusLabel": "Regional Approval",
    "metaDescription": "Beinaglutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Beinaglutide sits in a regional context, so good guidance means regulatory clarity first. This page frames what to verify before discussing protocol details.",
    "dosingSection": {
      "overview": "For Beinaglutide, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Beinaglutide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Beinaglutide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Beinaglutide may have incomplete long-term safety evidence; keep expectations conservative.",
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Beinaglutide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Beinaglutide: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Beinaglutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Beinaglutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Beinaglutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Beinaglutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Beinaglutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Beinaglutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Beinaglutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Beinaglutide",
    "subtitle": "Region-specific GLP-1 context with approval-boundary cautions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Regional Approval"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "boron",
    "title": "Boron",
    "aliases": [
      "B"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Boron guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Boron tracking is most useful when you link dose timing, tolerance, and symptom context in one log entry. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Boron should follow a steady cadence with periodic tolerance and response review. [C1]",
      "protocolPatterns": [
        "Keep Boron schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Boron timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Boron, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Boron: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Boron-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Boron: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Boron",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Boron: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Boron+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Boron",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "botulinum-toxin",
    "title": "Botulinum toxin",
    "aliases": [],
    "category": "Research Peptide",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Botulinum toxin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Botulinum toxin tracking improves fast once you define one clear objective and log against it every week. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For Botulinum toxin, stable cadence is the foundation for any useful adjustment discussion. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Botulinum toxin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Botulinum toxin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Botulinum toxin versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Botulinum toxin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Botulinum%20toxin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Botulinum toxin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Botulinum%20toxin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Botulinum toxin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Botulinum toxin",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "coach"
  },
  {
    "slug": "bpc-157",
    "title": "BPC-157",
    "aliases": [
      "Body Protection Compound 157"
    ],
    "category": "Healing Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "BPC-157 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "BPC-157 notes are only useful when they tie symptoms to location, timeline, and load. Vague better or worse entries hide patterns. This guide pushes objective context over wishful interpretation.",
    "dosingSection": {
      "overview": "For BPC-157, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for BPC-157 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log BPC-157 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "BPC-157 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for BPC-157 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BPC-157: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=BPC-157",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BPC-157: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=BPC-157",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BPC-157: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BPC-157",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "BPC-157: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BPC-157+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "BPC-157",
    "subtitle": "Recovery-focused peptide logging with context-rich progress notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "bpc-500mcg-plus-tb500-500mcg-blend",
    "title": "BPC 500mcg+TB500 500mcg Blend",
    "aliases": [
      "BPC 500mcg+TB500 500mcg Blend"
    ],
    "category": "Compound Blend",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "BPC 500mcg+TB500 500mcg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For BPC-157 + TB-500 Blend, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "BPC-157 + TB-500 Blend requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Treat BPC-157 + TB-500 Blend as a multi-signal protocol and define what each component is expected to influence. [C2]",
        "Do not add new stacked compounds mid-cycle unless you can isolate effects clearly. [C3]"
      ],
      "monitoringWindows": [
        "Log component-related outcomes separately before making blend-level conclusions. [C2]",
        "Escalate unusual reactions quickly since blend attribution is inherently less precise. [C3]"
      ]
    },
    "trackingSignals": [
      "Log BPC-157 + TB-500 Blend timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "BPC-157 + TB-500 Blend may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for BPC-157 + TB-500 Blend versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BPC 500mcg+TB500 500mcg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BPC%20500mcg%2BTB500%20500mcg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BPC 500mcg+TB500 500mcg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BPC%20500mcg%2BTB500%20500mcg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BPC 500mcg+TB500 500mcg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "BPC-157 + TB-500 Blend",
    "subtitle": "BPC-157 + TB-500 blend with component-aware tracking context.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [
      {
        "name": "BPC-157",
        "amount": "500mcg"
      },
      {
        "name": "TB-500",
        "amount": "500mcg"
      }
    ],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "bpc157-10mg-plus-tb500-10mg-blend",
    "title": "BPC157 10mg+TB500 10mg Blend",
    "aliases": [
      "BPC157 10mg+TB500 10mg Blend"
    ],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "BPC157 10mg+TB500 10mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For BPC-157 + TB-500 Blend, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "BPC-157 + TB-500 Blend requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Treat BPC-157 + TB-500 Blend as a multi-signal protocol and define what each component is expected to influence. [C2]",
        "Do not add new stacked compounds mid-cycle unless you can isolate effects clearly. [C3]"
      ],
      "monitoringWindows": [
        "Log component-related outcomes separately before making blend-level conclusions. [C2]",
        "Escalate unusual reactions quickly since blend attribution is inherently less precise. [C3]"
      ]
    },
    "trackingSignals": [
      "Log BPC-157 + TB-500 Blend timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "BPC-157 + TB-500 Blend may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for BPC-157 + TB-500 Blend versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BPC157 10mg+TB500 10mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BPC157%2010mg%2BTB500%2010mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BPC157 10mg+TB500 10mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BPC157%2010mg%2BTB500%2010mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BPC157 10mg+TB500 10mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "BPC-157 + TB-500 Blend",
    "subtitle": "BPC-157 + TB-500 blend with component-aware tracking context.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [
      {
        "name": "BPC-157",
        "amount": "10mg"
      },
      {
        "name": "TB-500",
        "amount": "10mg"
      }
    ],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "bpc157-5mg-plus-tb500-5mg-blend",
    "title": "BPC157 5mg+TB500 5mg Blend",
    "aliases": [
      "BPC157 5mg+TB500 5mg Blend"
    ],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "BPC157 5mg+TB500 5mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "BPC-157 + TB-500 Blend should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For BPC-157 + TB-500 Blend, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Treat BPC-157 + TB-500 Blend as a multi-signal protocol and define what each component is expected to influence. [C2]",
        "Do not add new stacked compounds mid-cycle unless you can isolate effects clearly. [C3]"
      ],
      "monitoringWindows": [
        "Log component-related outcomes separately before making blend-level conclusions. [C2]",
        "Escalate unusual reactions quickly since blend attribution is inherently less precise. [C3]"
      ]
    },
    "trackingSignals": [
      "Log BPC-157 + TB-500 Blend timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "BPC-157 + TB-500 Blend may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for BPC-157 + TB-500 Blend versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BPC157 5mg+TB500 5mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BPC157%205mg%2BTB500%205mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BPC157 5mg+TB500 5mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BPC157%205mg%2BTB500%205mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BPC157 5mg+TB500 5mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "BPC-157 + TB-500 Blend",
    "subtitle": "BPC-157 + TB-500 blend with component-aware tracking context.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [
      {
        "name": "BPC-157",
        "amount": "5mg"
      },
      {
        "name": "TB-500",
        "amount": "5mg"
      }
    ],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "bu-equipoise",
    "title": "BU(EQUIPOISE)",
    "aliases": [
      "BU(EQUIPOISE)"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "BU(EQUIPOISE) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "BU should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "BU requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for BU and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact BU timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "BU may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is BU appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BU(EQUIPOISE): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BU",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BU(EQUIPOISE): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BU",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BU(EQUIPOISE): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "BU",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "cabergoline",
    "title": "Cabergoline",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Cabergoline guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Cabergoline is easier to judge when your notes read like a timeline instead of scattered snapshots. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "With Cabergoline, consistency beats complexity. Hold one clean routine long enough to produce signal. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Cabergoline and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Cabergoline timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Cabergoline appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Cabergoline: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Cabergoline",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Cabergoline: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Cabergoline",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Cabergoline: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Cabergoline",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach"
  },
  {
    "slug": "cagrilintide",
    "title": "Cagrilintide",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Cagrilintide guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Cagrilintide changes appetite patterns in ways that can be subtle at first. Better logs capture timing and meal context, not just total intake.",
    "dosingSection": {
      "overview": "For Cagrilintide, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Cagrilintide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Cagrilintide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Cagrilintide may have incomplete long-term safety evidence; keep expectations conservative.",
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Cagrilintide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Cagrilintide: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Cagrilintide",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Cagrilintide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Cagrilintide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Cagrilintide: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Cagrilintide",
    "subtitle": "Amylin-pathway peptide context with appetite-pattern emphasis.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "cagrilintide-5mg-plus-semaglutide-5mg-blend",
    "title": "Cagrilintide 5mg+Semaglutide 5mg Blend",
    "aliases": [
      "Cagrilintide 5mg+Semaglutide 5mg Blend"
    ],
    "category": "Research Peptide",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Cagrilintide 5mg+Semaglutide 5mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Cagrilintide + Semaglutide Blend tracking should emphasize repeatability so your clinician can separate trend from noise quickly. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For Cagrilintide + Semaglutide Blend, protocol moves are safer when escalation is tied to documented tolerance windows. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Cagrilintide + Semaglutide Blend so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Cagrilintide + Semaglutide Blend dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Cagrilintide + Semaglutide Blend titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Cagrilintide 5mg+Semaglutide 5mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Cagrilintide%205mg%2BSemaglutide%205mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Cagrilintide 5mg+Semaglutide 5mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Cagrilintide%205mg%2BSemaglutide%205mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Cagrilintide 5mg+Semaglutide 5mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Cagrilintide + Semaglutide Blend",
    "subtitle": "Cagrilintide + Semaglutide blend with component-aware tracking context.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [
      {
        "name": "Cagrilintide",
        "amount": "5mg"
      },
      {
        "name": "Semaglutide",
        "amount": "5mg"
      }
    ],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "clinical"
  },
  {
    "slug": "cagrisema",
    "title": "CagriSema",
    "aliases": [
      "Cagrilintide + Semaglutide"
    ],
    "category": "Experimental",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "CagriSema guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "CagriSema is not just Semaglutide plus one more thing. Combination therapies can change both appetite dynamics and side-effect profile, so this guide emphasizes structured comparison across cycles.",
    "dosingSection": {
      "overview": "CagriSema requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for CagriSema so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each CagriSema dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "CagriSema may have incomplete long-term safety evidence; keep expectations conservative.",
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should CagriSema titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "CagriSema: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=CagriSema",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "CagriSema: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=CagriSema",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "CagriSema: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=CagriSema",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "CagriSema: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=CagriSema+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "CagriSema",
    "subtitle": "Combination pathway guide for layered appetite and tolerance patterns.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "calcium",
    "title": "Calcium",
    "aliases": [
      "Ca"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Calcium guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Calcium works best as a steady support protocol with measured check-ins rather than short reactive cycles. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Calcium decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Keep Calcium schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Calcium timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Calcium, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Calcium: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Calcium-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Calcium: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Calcium",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Calcium: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Calcium+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Calcium",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "cerebrolysin",
    "title": "Cerebrolysin",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Cerebrolysin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Cerebrolysin belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "Cerebrolysin should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Cerebrolysin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Cerebrolysin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Cerebrolysin may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Cerebrolysin versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Cerebrolysin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Cerebrolysin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Cerebrolysin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Cerebrolysin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Cerebrolysin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Cerebrolysin",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "chloride",
    "title": "Chloride",
    "aliases": [
      "Cl"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Chloride guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Chloride looks simple, but better results usually come from routine, timing consistency, and objective follow-up. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Chloride decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Keep Chloride schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Chloride timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Chloride, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Chloride: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/list-all/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Chloride: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Chloride",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Chloride: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Chloride+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Chloride",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "chromium",
    "title": "Chromium",
    "aliases": [
      "Cr"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Chromium guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Chromium works best as a steady support protocol with measured check-ins rather than short reactive cycles. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Chromium decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Keep Chromium schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Chromium timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Chromium, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Chromium: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Chromium-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Chromium: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Chromium",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Chromium: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Chromium+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Chromium",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "cjc-1295",
    "title": "CJC-1295",
    "aliases": [
      "CJC1295 (no DAC)",
      "CJC-1295 Without DAC"
    ],
    "category": "GH Secretagogue",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "CJC-1295 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Non-DAC CJC-1295 is timing-sensitive in practice. If you stack it, you need explicit stack metadata in every meaningful note.",
    "dosingSection": {
      "overview": "CJC-1295 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for CJC-1295 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log CJC-1295 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "CJC-1295 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for CJC-1295 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "CJC-1295: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=CJC-1295",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "CJC-1295: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=CJC-1295",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "CJC-1295: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=CJC-1295",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "CJC-1295: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "CJC-1295",
    "subtitle": "CJC-1295 non-DAC cadence guide for stack-aware tracking.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "cjc-1295-without-dac-5mg-plus-ipa-5mg-blend",
    "title": "CJC-1295 without DAC 5mg + IPA 5mg Blend",
    "aliases": [
      "CJC-1295 without DAC 5mg + IPA 5mg Blend"
    ],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "CJC-1295 without DAC 5mg + IPA 5mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "CJC 1295 Without DAC + Ipamorelin Blend belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "CJC 1295 Without DAC + Ipamorelin Blend requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Treat CJC 1295 Without DAC + Ipamorelin Blend as a multi-signal protocol and define what each component is expected to influence. [C2]",
        "Do not add new stacked compounds mid-cycle unless you can isolate effects clearly. [C3]"
      ],
      "monitoringWindows": [
        "Log component-related outcomes separately before making blend-level conclusions. [C2]",
        "Escalate unusual reactions quickly since blend attribution is inherently less precise. [C3]"
      ]
    },
    "trackingSignals": [
      "Log CJC 1295 Without DAC + Ipamorelin Blend timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "CJC 1295 Without DAC + Ipamorelin Blend may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for CJC 1295 Without DAC + Ipamorelin Blend versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "CJC-1295 without DAC 5mg + IPA 5mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295%20without%20DAC%205mg%20%2B%20IPA%205mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "CJC-1295 without DAC 5mg + IPA 5mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=CJC-1295%20without%20DAC%205mg%20%2B%20IPA%205mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "CJC-1295 without DAC 5mg + IPA 5mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "CJC 1295 Without DAC + Ipamorelin Blend",
    "subtitle": "CJC 1295 Without DAC + Ipamorelin blend with component-aware tracking context.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [
      {
        "name": "CJC 1295 Without DAC",
        "amount": "5mg"
      },
      {
        "name": "Ipamorelin",
        "amount": "5mg"
      }
    ],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "cjc-dac",
    "title": "CJC-1295 DAC",
    "aliases": [
      "CJC-DAC",
      "CJC-1295 With DAC"
    ],
    "category": "GH Secretagogue",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "CJC-1295 DAC guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "CJC-DAC discussions should include cycle boundaries up front. Longer-acting compounds demand cleaner stop criteria and clearer reassessment checkpoints.",
    "dosingSection": {
      "overview": "CJC-1295 DAC should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for CJC-1295 DAC and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log CJC-1295 DAC timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "CJC-1295 DAC may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for CJC-1295 DAC versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "CJC-1295 DAC: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=CJC-1295%20DAC",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "CJC-1295 DAC: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=CJC-1295%20DAC",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "CJC-1295 DAC: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=CJC-1295%20DAC",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "CJC-1295 DAC: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295%20DAC+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "CJC-1295 DAC",
    "subtitle": "Longer-acting CJC-DAC overview with cycle-boundary safeguards.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "clenbuterol",
    "title": "CLENBUTEROL",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "CLENBUTEROL guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "CLENBUTEROL should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For CLENBUTEROL, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for CLENBUTEROL and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact CLENBUTEROL timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "CLENBUTEROL may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is CLENBUTEROL appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "CLENBUTEROL: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=CLENBUTEROL",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "CLENBUTEROL: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=CLENBUTEROL",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "CLENBUTEROL: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "CLENBUTEROL",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "clomid",
    "title": "Clomid",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Clomid guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Clomid tracking improves fast once you define one clear objective and log against it every week. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For Clomid, stable cadence is the foundation for any useful adjustment discussion. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Clomid and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Clomid timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Clomid appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Clomid: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Clomid",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Clomid: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Clomid",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Clomid: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Clomid",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach"
  },
  {
    "slug": "cock-bombs",
    "title": "COCK BOMBS",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "COCK BOMBS guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "COCK BOMBS belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "COCK BOMBS should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for COCK BOMBS and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact COCK BOMBS timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "COCK BOMBS may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is COCK BOMBS appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "COCK BOMBS: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=COCK%20BOMBS",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "COCK BOMBS: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=COCK%20BOMBS",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "COCK BOMBS: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "COCK BOMBS",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "copper",
    "title": "Copper",
    "aliases": [
      "Cu"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Copper guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Copper looks simple, but better results usually come from routine, timing consistency, and objective follow-up. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Copper decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Keep Copper schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Copper timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Copper, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Copper: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Copper-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Copper: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Copper",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Copper: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Copper+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Copper",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "d320",
    "title": "D320",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "D320 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "D320 belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For D320, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for D320 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact D320 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "D320 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is D320 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "D320: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=D320",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "D320: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=D320",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "D320: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "D320",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "danuglipron",
    "title": "Danuglipron",
    "aliases": [
      "PF-06882961"
    ],
    "category": "Experimental",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Danuglipron guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Danuglipron has generated interest because it is oral, but route convenience does not reduce uncertainty. Log adherence and side effects tightly if it ever enters your care discussions.",
    "dosingSection": {
      "overview": "Danuglipron requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Danuglipron so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Danuglipron dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Danuglipron may have incomplete long-term safety evidence; keep expectations conservative.",
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Danuglipron titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Danuglipron: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Danuglipron",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Danuglipron: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Danuglipron",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Danuglipron: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Danuglipron",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Danuglipron: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Danuglipron+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Danuglipron",
    "subtitle": "Investigational oral incretin context and adherence framing.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "GLP-1/GIP",
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "deca-nd",
    "title": "DECA(ND)",
    "aliases": [
      "DECA(ND)"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "DECA(ND) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For DECA, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "DECA should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for DECA and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact DECA timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "DECA may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is DECA appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "DECA(ND): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=DECA",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "DECA(ND): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=DECA",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "DECA(ND): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "DECA",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "dermorphin",
    "title": "Dermorphin",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Dermorphin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Dermorphin belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "Dermorphin requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Dermorphin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Dermorphin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Dermorphin may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Dermorphin versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Dermorphin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Dermorphin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Dermorphin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Dermorphin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Dermorphin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Dermorphin",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "dhb-1-test-cyp",
    "title": "DHB(1-Test Cyp)",
    "aliases": [
      "DHB(1-Test Cyp)"
    ],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "DHB(1-Test Cyp) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For DHB, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "DHB requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for DHB and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact DHB timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "DHB may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is DHB appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "DHB(1-Test Cyp): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=DHB",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "DHB(1-Test Cyp): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=DHB",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "DHB(1-Test Cyp): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "DHB",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "dht-stanolone",
    "title": "DHT (Stanolone)",
    "aliases": [
      "DHT (Stanolone)"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "DHT (Stanolone) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "DHT should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "DHT requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for DHT and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact DHT timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "DHT may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is DHT appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "DHT (Stanolone): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=DHT",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "DHT (Stanolone): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=DHT",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "DHT (Stanolone): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "DHT",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "dianabol",
    "title": "DIANABOL",
    "aliases": [
      "DIANABOL(Methandrostenolone)"
    ],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "DIANABOL guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "DIANABOL should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "DIANABOL should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for DIANABOL and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact DIANABOL timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "DIANABOL may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is DIANABOL appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "DIANABOL: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=DIANABOL",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "DIANABOL: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=DIANABOL",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "DIANABOL: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "DIANABOL",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "dihexa",
    "title": "Dihexa",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Dihexa guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Dihexa, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For Dihexa, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Dihexa and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Dihexa timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Dihexa may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Dihexa appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Dihexa: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Dihexa",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Dihexa: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Dihexa",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Dihexa: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Dihexa",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "dnp",
    "title": "DNP",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "DNP guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For DNP, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For DNP, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for DNP and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact DNP timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "DNP may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is DNP appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "DNP: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=DNP",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "DNP: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=DNP",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "DNP: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "DNP",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "dsip",
    "title": "DSIP",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "DSIP guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "DSIP belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "DSIP requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for DSIP and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log DSIP timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "DSIP may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for DSIP versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "DSIP: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=DSIP",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "DSIP: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=DSIP",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "DSIP: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "DSIP",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "dulaglutide",
    "title": "Dulaglutide",
    "aliases": [
      "Trulicity"
    ],
    "category": "GLP-1",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Dulaglutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Dulaglutide rewards routine. If your logs keep shifting day-to-day, you lose the trend. This guide helps you keep adherence, GI response, and weight trajectory readable over long windows.",
    "dosingSection": {
      "overview": "For Dulaglutide, protocol moves are safer when escalation is tied to documented tolerance windows. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Dulaglutide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Dulaglutide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Dulaglutide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Dulaglutide: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Dulaglutide&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Dulaglutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Dulaglutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Dulaglutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Dulaglutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Dulaglutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Dulaglutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Dulaglutide",
    "subtitle": "Long-acting weekly GLP-1 with consistency-first tracking priorities.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "clinical"
  },
  {
    "slug": "dutasteride",
    "title": "Dutasteride",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Dutasteride guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Dutasteride tracking improves fast once you define one clear objective and log against it every week. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "With Dutasteride, consistency beats complexity. Hold one clean routine long enough to produce signal. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Dutasteride and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Dutasteride timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Dutasteride appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Dutasteride: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Dutasteride",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Dutasteride: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Dutasteride",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Dutasteride: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Dutasteride",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach"
  },
  {
    "slug": "ecnoglutide",
    "title": "Ecnoglutide",
    "aliases": [
      "XW003"
    ],
    "category": "Experimental",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Ecnoglutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Ecnoglutide belongs in a risk-managed conversation, not a shortcut conversation. Keep objective markers and escalation boundaries explicit.",
    "dosingSection": {
      "overview": "Ecnoglutide requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Ecnoglutide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Ecnoglutide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Ecnoglutide may have incomplete long-term safety evidence; keep expectations conservative.",
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Ecnoglutide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Ecnoglutide: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Ecnoglutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Ecnoglutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ecnoglutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Ecnoglutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Ecnoglutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Ecnoglutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Ecnoglutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Ecnoglutide",
    "subtitle": "Research-stage metabolic peptide with protocol-boundary emphasis.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "efpeglenatide",
    "title": "Efpeglenatide",
    "aliases": [
      "AMG 133 (historical context)"
    ],
    "category": "GLP-1",
    "status": "discontinued",
    "statusLabel": "Discontinued/Legacy",
    "metaDescription": "Efpeglenatide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Efpeglenatide is best handled as a historical or legacy reference. Verify what is current, what is discontinued, and what is still clinically relevant before drawing conclusions.",
    "dosingSection": {
      "overview": "For Efpeglenatide, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Efpeglenatide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Efpeglenatide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Efpeglenatide may have incomplete long-term safety evidence; keep expectations conservative.",
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Efpeglenatide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Efpeglenatide: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Efpeglenatide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Efpeglenatide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Efpeglenatide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Efpeglenatide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Efpeglenatide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Efpeglenatide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Efpeglenatide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Efpeglenatide",
    "subtitle": "Legacy/discontinued pathway with source-verification focus.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Discontinued"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "epithalon",
    "title": "Epithalon",
    "aliases": [
      "Epitalon"
    ],
    "category": "Anti-Aging Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Epithalon guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Epithalon is often discussed with sweeping longevity claims. This page is intentionally practical: track what can be observed and avoid storytelling leaps.",
    "dosingSection": {
      "overview": "Epithalon requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Epithalon and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Epithalon timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Epithalon may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Epithalon versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Epithalon: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Epithalon",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Epithalon: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Epithalon",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Epithalon: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Epithalon",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Epithalon: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Epithalon+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Epithalon",
    "subtitle": "Epithalon anti-aging peptide context with evidence realism.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "epo",
    "title": "EPO",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "EPO guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "EPO belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For EPO, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for EPO and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log EPO timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "EPO may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for EPO versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "EPO: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=EPO",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "EPO: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=EPO",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "EPO: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "EPO",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "estradial-cypionate",
    "title": "Estradial Cypionate",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Estradial Cypionate guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Estradial Cypionate should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Estradial Cypionate requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Estradial Cypionate and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Estradial Cypionate timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Estradial Cypionate may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Estradial Cypionate appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Estradial Cypionate: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Estradial%20Cypionate",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Estradial Cypionate: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Estradial%20Cypionate",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Estradial Cypionate: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Estradial Cypionate",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "exenatide",
    "title": "Exenatide",
    "aliases": [
      "Byetta",
      "Bydureon"
    ],
    "category": "GLP-1",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Exenatide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Exenatide has two very different use patterns. If your notes do not reflect formulation and schedule differences, trend interpretation breaks. This guide keeps those pathways separate and clear.",
    "dosingSection": {
      "overview": "Exenatide should be reviewed over structured intervals, not single difficult days. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Exenatide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Exenatide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Exenatide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Exenatide: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Exenatide&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Exenatide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Exenatide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Exenatide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Exenatide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Exenatide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Exenatide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Exenatide",
    "subtitle": "Immediate vs extended-release GLP-1 workflow distinctions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "clinical"
  },
  {
    "slug": "finasteride",
    "title": "Finasteride",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Finasteride guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Finasteride is easier to judge when your notes read like a timeline instead of scattered snapshots. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Finasteride protocols are easier to interpret when you avoid changing multiple variables at once. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Finasteride and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Finasteride timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Finasteride appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Finasteride: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Finasteride",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Finasteride: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Finasteride",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Finasteride: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Finasteride",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach"
  },
  {
    "slug": "flibanserin",
    "title": "Flibanserin",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Flibanserin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Flibanserin, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Flibanserin should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Flibanserin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Flibanserin timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Flibanserin may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Flibanserin appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Flibanserin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Flibanserin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Flibanserin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Flibanserin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Flibanserin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Flibanserin",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "fluoxymesterone-halotestin",
    "title": "Fluoxymesterone(Halotestin)",
    "aliases": [
      "Fluoxymesterone(Halotestin)"
    ],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Fluoxymesterone(Halotestin) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Fluoxymesterone, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Fluoxymesterone requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Fluoxymesterone and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Fluoxymesterone timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Fluoxymesterone may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Fluoxymesterone appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Fluoxymesterone(Halotestin): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Fluoxymesterone",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Fluoxymesterone(Halotestin): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Fluoxymesterone",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Fluoxymesterone(Halotestin): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Fluoxymesterone",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "follistatin",
    "title": "Follistatin",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Follistatin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Follistatin should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "Follistatin should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Follistatin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Follistatin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Follistatin may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Follistatin versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Follistatin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Follistatin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Follistatin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Follistatin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Follistatin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Follistatin",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "foxo4",
    "title": "FOXO4",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "FOXO4 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For FOXO4, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "FOXO4 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for FOXO4 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log FOXO4 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "FOXO4 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for FOXO4 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "FOXO4: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=FOXO4",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "FOXO4: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=FOXO4",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "FOXO4: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "FOXO4",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "fragment-176-191",
    "title": "Fragment 176-191",
    "aliases": [
      "HGH Fragment 176-191"
    ],
    "category": "Fat Loss Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Fragment 176-191 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Fragment 176-191 is often marketed aggressively. This guide is built to keep claims grounded and to separate tracking evidence from narrative momentum.",
    "dosingSection": {
      "overview": "For Fragment 176-191, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Fragment 176-191 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Fragment 176-191 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Fragment 176-191 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Fragment 176-191 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Fragment 176-191: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Fragment%20176-191",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Fragment 176-191: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Fragment%20176-191",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Fragment 176-191: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Fragment%20176-191",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Fragment 176-191: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Fragment%20176-191+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Fragment 176-191",
    "subtitle": "Fat-loss peptide context with strict expectation management.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "gaz",
    "title": "GAZ",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "GAZ guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For GAZ, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "GAZ requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for GAZ and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact GAZ timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "GAZ may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is GAZ appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "GAZ: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GAZ",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "GAZ: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GAZ",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "GAZ: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "GAZ",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "ghk-cu",
    "title": "GHK-CU",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "GHK-CU guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "GHK-CU appears in many formulations. The useful work is documenting route, formulation, and response timeline clearly enough to compare cycles.",
    "dosingSection": {
      "overview": "For GHK-CU, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for GHK-CU and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log GHK-CU timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "GHK-CU may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for GHK-CU versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "GHK-CU: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GHK-CU",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "GHK-CU: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GHK-CU",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "GHK-CU: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "GHK-CU",
    "subtitle": "GHK-CU support guide with route and response-context tracking.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "ghrp-2",
    "title": "GHRP-2",
    "aliases": [
      "Growth Hormone Releasing Peptide-2"
    ],
    "category": "GH Secretagogue",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "GHRP-2 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "GHRP-2 can shift appetite and stress-response perception quickly. This guide emphasizes structured symptom timing so interpretation stays anchored.",
    "dosingSection": {
      "overview": "GHRP-2 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for GHRP-2 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log GHRP-2 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "GHRP-2 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for GHRP-2 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "GHRP-2: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=GHRP-2",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "GHRP-2: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=GHRP-2",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "GHRP-2: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GHRP-2",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "GHRP-2: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GHRP-2+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "GHRP-2",
    "subtitle": "GHRP-2 context with appetite and tolerance monitoring priorities.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "ghrp-2-acetate",
    "title": "GHRP-2 Acetate",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "GHRP-2 Acetate guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For GHRP-2 Acetate, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "GHRP-2 Acetate requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for GHRP-2 Acetate and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log GHRP-2 Acetate timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "GHRP-2 Acetate may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for GHRP-2 Acetate versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "GHRP-2 Acetate: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GHRP-2%20Acetate",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "GHRP-2 Acetate: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GHRP-2%20Acetate",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "GHRP-2 Acetate: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "GHRP-2 Acetate",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "ghrp-6",
    "title": "GHRP-6",
    "aliases": [
      "Growth Hormone Releasing Peptide-6"
    ],
    "category": "GH Secretagogue",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "GHRP-6 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "GHRP-6 often changes hunger signaling in ways users underestimate. Good logs here are about timing and magnitude, not just yes or no effects.",
    "dosingSection": {
      "overview": "For GHRP-6, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for GHRP-6 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log GHRP-6 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "GHRP-6 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for GHRP-6 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "GHRP-6: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=GHRP-6",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "GHRP-6: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=GHRP-6",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "GHRP-6: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GHRP-6",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "GHRP-6: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GHRP-6+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "GHRP-6",
    "subtitle": "GHRP-6 tracking guide with hunger-signal framing.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "ghrp-6-acetate",
    "title": "GHRP-6 Acetate",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "GHRP-6 Acetate guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For GHRP-6 Acetate, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For GHRP-6 Acetate, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for GHRP-6 Acetate and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log GHRP-6 Acetate timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "GHRP-6 Acetate may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for GHRP-6 Acetate versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "GHRP-6 Acetate: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GHRP-6%20Acetate",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "GHRP-6 Acetate: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GHRP-6%20Acetate",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "GHRP-6 Acetate: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "GHRP-6 Acetate",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "glow-ghk-cu-50mg-plus-tb500-10mg-plus-bpc157-10mg-blend",
    "title": "(GLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg Blend",
    "aliases": [
      "(GLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg Blend"
    ],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "(GLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "GLOW is a vendor-named blend, so clarity comes from component-level tracking. Treat it as three interacting signals, not one monolithic effect.",
    "dosingSection": {
      "overview": "GLOW requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Treat GLOW as a multi-signal protocol and define what each component is expected to influence. [C2]",
        "Do not add new stacked compounds mid-cycle unless you can isolate effects clearly. [C3]"
      ],
      "monitoringWindows": [
        "Log component-related outcomes separately before making blend-level conclusions. [C2]",
        "Escalate unusual reactions quickly since blend attribution is inherently less precise. [C3]"
      ]
    },
    "trackingSignals": [
      "Log GLOW timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "GLOW may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for GLOW versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "(GLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GHK-CU%2050mg%2BTB500%2010mg%2BBPC157%2010mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "(GLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GHK-CU%2050mg%2BTB500%2010mg%2BBPC157%2010mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "(GLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "GLOW",
    "subtitle": "GHK-CU + TB-500 + BPC-157 blend.",
    "acronymInfo": {
      "code": "GLOW",
      "meaning": null,
      "isVendorDefined": true,
      "note": "Vendor acronym; full expansion not published in source material."
    },
    "composition": [
      {
        "name": "GHK-CU",
        "amount": "50mg"
      },
      {
        "name": "TB-500",
        "amount": "10mg"
      },
      {
        "name": "BPC-157",
        "amount": "10mg"
      }
    ],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "glutathione",
    "title": "Glutathione",
    "aliases": [
      "GSH"
    ],
    "category": "Antioxidant",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "Glutathione guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Glutathione tracking is most useful when you include formulation, handling, and timing details that usually get skipped in casual notes.",
    "dosingSection": {
      "overview": "For Glutathione, conservative adjustments and measured rechecks are safer than abrupt protocol jumps. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Glutathione and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Glutathione timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Glutathione appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Glutathione: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Glutathione&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Glutathione: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Glutathione",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Glutathione: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Glutathione",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Glutathione: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Glutathione+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Glutathione",
    "subtitle": "Glutathione support guide with formulation and handling context.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "gonadorelin",
    "title": "Gonadorelin",
    "aliases": [],
    "category": "Research Peptide",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "Gonadorelin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "With gonadorelin, context is everything: baseline axis status, intended objective, and lab timing all matter more than anecdote quality.",
    "dosingSection": {
      "overview": "Gonadorelin decisions should follow objective trend checks, not reactive day-to-day interpretation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Gonadorelin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Gonadorelin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Gonadorelin versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Gonadorelin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Gonadorelin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Gonadorelin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Gonadorelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Gonadorelin: MedlinePlus safety and interaction context",
        "url": "https://medlineplus.gov/?query=Gonadorelin",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Gonadorelin",
    "subtitle": "Gonadorelin guide with hormone-axis monitoring checkpoints.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Hormone",
        "Injectable Compound",
        "Supportive"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "clinical"
  },
  {
    "slug": "gw-501516-cardarine",
    "title": "GW-501516(Cardarine)",
    "aliases": [
      "GW-501516(Cardarine)"
    ],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "GW-501516(Cardarine) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "GW-501516 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For GW-501516, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for GW-501516 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact GW-501516 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "GW-501516 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is GW-501516 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "GW-501516(Cardarine): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GW-501516",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "GW-501516(Cardarine): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GW-501516",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "GW-501516(Cardarine): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "GW-501516",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "hcg",
    "title": "Human Chorionic Gonadotropin (HCG)",
    "aliases": [
      "Pregnyl",
      "Ovidrel",
      "HCG",
      "Human Chorionic Gonadotropin (HCG)"
    ],
    "category": "Hormone",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Human Chorionic Gonadotropin (HCG) guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "HCG tracking only becomes useful when dose schedule and lab cadence are aligned. This page keeps those two systems connected so trend review stays meaningful.",
    "dosingSection": {
      "overview": "Human Chorionic Gonadotropin should be reviewed over structured intervals, not single difficult days. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Human Chorionic Gonadotropin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Human Chorionic Gonadotropin timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Human Chorionic Gonadotropin appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Human Chorionic Gonadotropin (HCG): FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Human%20Chorionic%20Gonadotropin&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Human Chorionic Gonadotropin (HCG): DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Human%20Chorionic%20Gonadotropin",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Human Chorionic Gonadotropin (HCG): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Human%20Chorionic%20Gonadotropin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Human Chorionic Gonadotropin (HCG): PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Human%20Chorionic%20Gonadotropin+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Human Chorionic Gonadotropin",
    "subtitle": "HCG hormone-support workflow with schedule and lab alignment.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Hormone",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "clinical"
  },
  {
    "slug": "hexarelin",
    "title": "Hexarelin",
    "aliases": [
      "Examorelin"
    ],
    "category": "GH Secretagogue",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Hexarelin guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Hexarelin gets attention for potency, but that is exactly why the risk conversation matters. This guide favors conservative cycles and clear reassessment points.",
    "dosingSection": {
      "overview": "Hexarelin requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Hexarelin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Hexarelin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Hexarelin may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Hexarelin versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Hexarelin: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Hexarelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Hexarelin: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Hexarelin",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Hexarelin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Hexarelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Hexarelin: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Hexarelin+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Hexarelin",
    "subtitle": "Potent secretagogue context with desensitization caution framing.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "hgh-191aa-somatropin",
    "title": "HGH 191AA (Somatropin)",
    "aliases": [
      "HGH 191AA (Somatropin)"
    ],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "HGH 191AA (Somatropin) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "HGH 191AA should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For HGH 191AA, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for HGH 191AA and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log HGH 191AA timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "HGH 191AA may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for HGH 191AA versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "HGH 191AA (Somatropin): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=HGH%20191AA",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "HGH 191AA (Somatropin): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=HGH%20191AA",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "HGH 191AA (Somatropin): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "HGH 191AA",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "hhb",
    "title": "HHB",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "HHB guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "HHB belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "HHB should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for HHB and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact HHB timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "HHB may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is HHB appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "HHB: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=HHB",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "HHB: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=HHB",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "HHB: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "HHB",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "hmg",
    "title": "HMG",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "HMG guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For HMG, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For HMG, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for HMG and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log HMG timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "HMG may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for HMG versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "HMG: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=HMG",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "HMG: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=HMG",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "HMG: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "HMG",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Hormone",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "hyaluronic-acid",
    "title": "Hyaluronic acid",
    "aliases": [],
    "category": "Research Peptide",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "Hyaluronic acid guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Hyaluronic acid works best as a steady support protocol with measured check-ins rather than short reactive cycles. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "Hyaluronic acid should follow a steady cadence with periodic tolerance and response review. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Hyaluronic acid and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Hyaluronic acid timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Hyaluronic acid versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Hyaluronic acid: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Hyaluronic%20acid",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Hyaluronic acid: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Hyaluronic%20acid",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Hyaluronic acid: MedlinePlus safety and interaction context",
        "url": "https://medlineplus.gov/?query=Hyaluronic%20acid",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Hyaluronic acid",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound",
        "Supportive"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "support"
  },
  {
    "slug": "igf-1lr3",
    "title": "IGF-1LR3",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "IGF-1LR3 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "IGF-1LR3 belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "IGF-1LR3 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for IGF-1LR3 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log IGF-1LR3 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "IGF-1LR3 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for IGF-1LR3 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "IGF-1LR3: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=IGF-1LR3",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "IGF-1LR3: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=IGF-1LR3",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "IGF-1LR3: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "IGF-1LR3",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "igf-des",
    "title": "IGF-DES",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "IGF-DES guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For IGF-DES, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "IGF-DES should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for IGF-DES and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log IGF-DES timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "IGF-DES may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for IGF-DES versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "IGF-DES: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=IGF-DES",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "IGF-DES: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=IGF-DES",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "IGF-DES: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "IGF-DES",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "insulin",
    "title": "Insulin",
    "aliases": [
      "Humalog",
      "Novolog",
      "Lantus",
      "Tresiba"
    ],
    "category": "Insulin",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Insulin guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Insulin belongs to a high-consequence category. This guide is built around safety infrastructure: glucose context, hypoglycemia handling, and clinician-directed adjustments.",
    "dosingSection": {
      "overview": "Insulin decisions should follow objective trend checks, not reactive day-to-day interpretation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Insulin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Insulin timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Insulin appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Insulin: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Insulin&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Insulin: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Insulin",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Insulin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Insulin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Insulin: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Insulin+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Insulin",
    "subtitle": "Insulin high-stakes tracking guide with safety-first guardrails.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Hormone",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "clinical"
  },
  {
    "slug": "iodine",
    "title": "Iodine",
    "aliases": [
      "I"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Iodine guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Iodine works best as a steady support protocol with measured check-ins rather than short reactive cycles. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "For Iodine, conservative adjustments and measured rechecks are safer than abrupt protocol jumps. [C1]",
      "protocolPatterns": [
        "Keep Iodine schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Iodine timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Iodine, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Iodine: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Iodine-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Iodine: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Iodine",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Iodine: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Iodine+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Iodine",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "ipamorelin",
    "title": "Ipamorelin",
    "aliases": [
      "IPA"
    ],
    "category": "GH Secretagogue",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Ipamorelin guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Ipamorelin logs get messy when timing floats. This guide centers dosing-window discipline and outcome notes that can survive clinician scrutiny.",
    "dosingSection": {
      "overview": "Ipamorelin should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Ipamorelin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Ipamorelin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Ipamorelin may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Ipamorelin versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Ipamorelin: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Ipamorelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Ipamorelin: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ipamorelin",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Ipamorelin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Ipamorelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Ipamorelin: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Ipamorelin+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Ipamorelin",
    "subtitle": "GH secretagogue use-pattern guide with timing discipline.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "iron",
    "title": "Iron",
    "aliases": [
      "Fe"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Iron guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Iron works best as a steady support protocol with measured check-ins rather than short reactive cycles. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Iron should follow a steady cadence with periodic tolerance and response review. [C1]",
      "protocolPatterns": [
        "Keep Iron schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Iron timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Iron, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Iron: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Iron-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Iron: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Iron",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Iron: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Iron+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Iron",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "isotretinoin",
    "title": "isotretinoin",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "isotretinoin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "isotretinoin tracking improves fast once you define one clear objective and log against it every week. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "With isotretinoin, consistency beats complexity. Hold one clean routine long enough to produce signal. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for isotretinoin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact isotretinoin timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is isotretinoin appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "isotretinoin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=isotretinoin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "isotretinoin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=isotretinoin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "isotretinoin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "isotretinoin",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach"
  },
  {
    "slug": "ivermectin",
    "title": "Ivermectin",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Ivermectin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Ivermectin should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Ivermectin requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Ivermectin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Ivermectin timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Ivermectin may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Ivermectin appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Ivermectin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Ivermectin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Ivermectin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Ivermectin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Ivermectin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Ivermectin",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "kisspeptin-10",
    "title": "KissPeptin-10",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "KissPeptin-10 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Kisspeptin-10 should be treated as endocrine-context sensitive. This page emphasizes clinician-led interpretation and careful biomarker follow-up.",
    "dosingSection": {
      "overview": "For KissPeptin-10, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for KissPeptin-10 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log KissPeptin-10 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "KissPeptin-10 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for KissPeptin-10 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "KissPeptin-10: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=KissPeptin-10",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "KissPeptin-10: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=KissPeptin-10",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "KissPeptin-10: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "KissPeptin-10",
    "subtitle": "Kisspeptin-10 reference guide for hormone-axis discussions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Hormone",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "klow-ghk-cu-50mg-plus-tb500-10mg-plus-bpc157-10mg-plus-kpv-10mg-blend",
    "title": "(KLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg Blend",
    "aliases": [
      "(KLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg Blend"
    ],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "(KLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "KLOW adds KPV into an already stacked blend, which increases interpretation complexity. This guide prioritizes disciplined logging and conservative conclusions.",
    "dosingSection": {
      "overview": "KLOW requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Treat KLOW as a multi-signal protocol and define what each component is expected to influence. [C2]",
        "Do not add new stacked compounds mid-cycle unless you can isolate effects clearly. [C3]"
      ],
      "monitoringWindows": [
        "Log component-related outcomes separately before making blend-level conclusions. [C2]",
        "Escalate unusual reactions quickly since blend attribution is inherently less precise. [C3]"
      ]
    },
    "trackingSignals": [
      "Log KLOW timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "KLOW may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for KLOW versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "(KLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GHK-CU%2050mg%2BTB500%2010mg%2BBPC157%2010mg%2BKPV%2010mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "(KLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GHK-CU%2050mg%2BTB500%2010mg%2BBPC157%2010mg%2BKPV%2010mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "(KLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "KLOW",
    "subtitle": "GHK-CU + TB-500 + BPC-157 + KPV blend.",
    "acronymInfo": {
      "code": "KLOW",
      "meaning": null,
      "isVendorDefined": true,
      "note": "Vendor acronym; full expansion not published in source material."
    },
    "composition": [
      {
        "name": "GHK-CU",
        "amount": "50mg"
      },
      {
        "name": "TB-500",
        "amount": "10mg"
      },
      {
        "name": "BPC-157",
        "amount": "10mg"
      },
      {
        "name": "KPV",
        "amount": "10mg"
      }
    ],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "kpv",
    "title": "KPV",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "KPV guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "KPV claims are broad and often loosely defined. This guide keeps your notes actionable by anchoring symptom windows and protocol boundaries.",
    "dosingSection": {
      "overview": "For KPV, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for KPV and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log KPV timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "KPV may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for KPV versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "KPV: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=KPV",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "KPV: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=KPV",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "KPV: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "KPV",
    "subtitle": "KPV peptide context with symptom-window tracking priorities.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "l-carnitine",
    "title": "L-Carnitine",
    "aliases": [
      "Levocarnitine"
    ],
    "category": "Amino Acid",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "L-Carnitine guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "L-carnitine can look straightforward until route-specific tolerance becomes the limiting factor. This page centers practical logging around that reality.",
    "dosingSection": {
      "overview": "L-Carnitine should follow a steady cadence with periodic tolerance and response review. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for L-Carnitine and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact L-Carnitine timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is L-Carnitine appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "L-Carnitine: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:L-Carnitine&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "L-Carnitine: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=L-Carnitine",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "L-Carnitine: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=L-Carnitine",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "L-Carnitine: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=L-Carnitine+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "L-Carnitine",
    "subtitle": "L-carnitine support guide with route-tolerance focus.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "lc425",
    "title": "LC425",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "LC425 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "LC425 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For LC425, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for LC425 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact LC425 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "LC425 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is LC425 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "LC425: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=LC425",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "LC425: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=LC425",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "LC425: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "LC425",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "lc500",
    "title": "LC500",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "LC500 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "LC500 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For LC500, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for LC500 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact LC500 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "LC500 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is LC500 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "LC500: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=LC500",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "LC500: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=LC500",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "LC500: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "LC500",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "lc526",
    "title": "LC526",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "LC526 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For LC526, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For LC526, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for LC526 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact LC526 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "LC526 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is LC526 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "LC526: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=LC526",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "LC526: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=LC526",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "LC526: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "LC526",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "lc553",
    "title": "LC553",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "LC553 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For LC553, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "LC553 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for LC553 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact LC553 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "LC553 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is LC553 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "LC553: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=LC553",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "LC553: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=LC553",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "LC553: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "LC553",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "letrozole",
    "title": "Letrozole",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Letrozole guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Letrozole is easier to judge when your notes read like a timeline instead of scattered snapshots. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "With Letrozole, consistency beats complexity. Hold one clean routine long enough to produce signal. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Letrozole and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Letrozole timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Letrozole appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Letrozole: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Letrozole",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Letrozole: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Letrozole",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Letrozole: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Letrozole",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach"
  },
  {
    "slug": "lgd-4033-ligandrol",
    "title": "LGD-4033(Ligandrol)",
    "aliases": [
      "LGD-4033(Ligandrol)"
    ],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "LGD-4033(Ligandrol) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "LGD-4033 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "LGD-4033 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for LGD-4033 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact LGD-4033 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "LGD-4033 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is LGD-4033 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "LGD-4033(Ligandrol): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=LGD-4033",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "LGD-4033(Ligandrol): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=LGD-4033",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "LGD-4033(Ligandrol): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "LGD-4033",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "lipo-c-120mg",
    "title": "Lipo-C 120mg",
    "aliases": [
      "Lipo-C 120mg"
    ],
    "category": "Injectable Compound",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "Lipo-C 120mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Lipo-C tracking is most useful when you link dose timing, tolerance, and symptom context in one log entry. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Lipo-C decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Lipo-C and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Lipo-C timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Lipo-C appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Lipo-C 120mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Lipo-C%20120mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Lipo-C 120mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Lipo-C%20120mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Lipo-C 120mg: MedlinePlus safety and interaction context",
        "url": "https://medlineplus.gov/?query=Lipo-C%20120mg",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Lipo-C",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound",
        "Supportive"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "lipo-c-216mg",
    "title": "Lipo-C 216mg",
    "aliases": [
      "Lipo-C 216mg"
    ],
    "category": "Injectable Compound",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "Lipo-C 216mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Lipo-C tracking is most useful when you link dose timing, tolerance, and symptom context in one log entry. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For Lipo-C, conservative adjustments and measured rechecks are safer than abrupt protocol jumps. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Lipo-C and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Lipo-C timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Lipo-C appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Lipo-C 216mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Lipo-C%20216mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Lipo-C 216mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Lipo-C%20216mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Lipo-C 216mg: MedlinePlus safety and interaction context",
        "url": "https://medlineplus.gov/?query=Lipo-C%20216mg",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Lipo-C",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound",
        "Supportive"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "liraglutide",
    "title": "Liraglutide",
    "aliases": [
      "Victoza",
      "Saxenda"
    ],
    "category": "GLP-1",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Liraglutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Liraglutide is a daily discipline game. The value is in repetition: same timing strategy, clean injection-site rotation, and symptom notes that do not blur into generic felt off entries.",
    "dosingSection": {
      "overview": "For Liraglutide, protocol moves are safer when escalation is tied to documented tolerance windows. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Liraglutide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Liraglutide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Liraglutide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Liraglutide: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Liraglutide&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Liraglutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Liraglutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Liraglutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Liraglutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Liraglutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Liraglutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Liraglutide",
    "subtitle": "Daily GLP-1 protocol guide centered on adherence and site rotation.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "clinical"
  },
  {
    "slug": "lixisenatide",
    "title": "Lixisenatide",
    "aliases": [
      "Adlyxin",
      "Lyxumia"
    ],
    "category": "GLP-1",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Lixisenatide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "With lixisenatide, meal timing and symptom timing can overlap fast. This page helps you separate drug effect from meal context so follow-up conversations stay concrete.",
    "dosingSection": {
      "overview": "Lixisenatide should be reviewed over structured intervals, not single difficult days. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Lixisenatide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Lixisenatide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Lixisenatide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Lixisenatide: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Lixisenatide&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Lixisenatide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lixisenatide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Lixisenatide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Lixisenatide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Lixisenatide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Lixisenatide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Lixisenatide",
    "subtitle": "Shorter-acting GLP-1 daily guide with meal-timing awareness.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "clinical"
  },
  {
    "slug": "ll37",
    "title": "LL37",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "LL37 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For LL37, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "LL37 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for LL37 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log LL37 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "LL37 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for LL37 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "LL37: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=LL37",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "LL37: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=LL37",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "LL37: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "LL37",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "lmx",
    "title": "LMX",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "LMX guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For LMX, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "LMX requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for LMX and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact LMX timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "LMX may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is LMX appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "LMX: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=LMX",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "LMX: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=LMX",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "LMX: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "LMX",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "magnesium",
    "title": "Magnesium",
    "aliases": [
      "Mg"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Magnesium guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Magnesium works best as a steady support protocol with measured check-ins rather than short reactive cycles. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Magnesium decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Keep Magnesium schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Magnesium timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Magnesium, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Magnesium: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Magnesium: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Magnesium",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Magnesium: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Magnesium+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Magnesium",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "manganese",
    "title": "Manganese",
    "aliases": [
      "Mn"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Manganese guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Manganese works best as a steady support protocol with measured check-ins rather than short reactive cycles. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Manganese should follow a steady cadence with periodic tolerance and response review. [C1]",
      "protocolPatterns": [
        "Keep Manganese schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Manganese timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Manganese, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Manganese: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Manganese-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Manganese: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Manganese",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Manganese: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Manganese+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Manganese",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "mast-blend-200mg",
    "title": "MAST Blend 200mg",
    "aliases": [
      "MAST Blend 200mg"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "MAST Blend 200mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For MAST Blend, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For MAST Blend, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Treat MAST Blend as a multi-signal protocol and define what each component is expected to influence. [C2]",
        "Do not add new stacked compounds mid-cycle unless you can isolate effects clearly. [C3]"
      ],
      "monitoringWindows": [
        "Log component-related outcomes separately before making blend-level conclusions. [C2]",
        "Escalate unusual reactions quickly since blend attribution is inherently less precise. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact MAST Blend timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "MAST Blend may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is MAST Blend appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MAST Blend 200mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MAST%20Blend%20200mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MAST Blend 200mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MAST%20Blend%20200mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MAST Blend 200mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "MAST Blend",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "mast-e-de",
    "title": "Mast E(DE)",
    "aliases": [
      "Mast E(DE)"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Mast E(DE) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Mast E belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Mast E should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Mast E and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Mast E timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Mast E may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Mast E appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Mast E(DE): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Mast%20E",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Mast E(DE): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Mast%20E",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Mast E(DE): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Mast E",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "mast-p-dp",
    "title": "Mast P(DP)",
    "aliases": [
      "Mast P(DP)"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Mast P(DP) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Mast P, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Mast P should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Mast P and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Mast P timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Mast P may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Mast P appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Mast P(DP): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Mast%20P",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Mast P(DP): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Mast%20P",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Mast P(DP): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Mast P",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "mazdutide",
    "title": "Mazdutide",
    "aliases": [
      "IBI362"
    ],
    "category": "Experimental",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Mazdutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Mazdutide discussions improve when progression is documented in small, interpretable steps rather than broad felt better summaries.",
    "dosingSection": {
      "overview": "Mazdutide should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Mazdutide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Mazdutide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Mazdutide may have incomplete long-term safety evidence; keep expectations conservative.",
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Mazdutide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Mazdutide: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Mazdutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Mazdutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Mazdutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Mazdutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Mazdutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Mazdutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Mazdutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Mazdutide",
    "subtitle": "Mazdutide investigational profile with careful progression tracking.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "melanotan-2",
    "title": "Melanotan II",
    "aliases": [
      "MT2"
    ],
    "category": "Other Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Melanotan II guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Melanotan II conversations should start with tolerability and risk, not cosmetic outcomes. This guide prioritizes side-effect surveillance and escalation thresholds.",
    "dosingSection": {
      "overview": "Melanotan II should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Melanotan II and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Melanotan II timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Melanotan II may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Melanotan II versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Melanotan II: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Melanotan%20II",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Melanotan II: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Melanotan%20II",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Melanotan II: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Melanotan%20II",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Melanotan II: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Melanotan%20II+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Melanotan II",
    "subtitle": "Melanotan II context with side-effect-first logging approach.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "melatonin",
    "title": "Melatonin",
    "aliases": [],
    "category": "Research Peptide",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "Melatonin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Melatonin looks simple, but better results usually come from routine, timing consistency, and objective follow-up. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "Melatonin decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Keep Melatonin schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Melatonin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Melatonin versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Melatonin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Melatonin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Melatonin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Melatonin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Melatonin: MedlinePlus safety and interaction context",
        "url": "https://medlineplus.gov/?query=Melatonin",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Melatonin",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound",
        "Vitamin",
        "Supportive"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "support"
  },
  {
    "slug": "ment-trestolone-acetate",
    "title": "MENT (Trestolone acetate)",
    "aliases": [
      "MENT (Trestolone acetate)"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "MENT (Trestolone acetate) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For MENT, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "MENT should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for MENT and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact MENT timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "MENT may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is MENT appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MENT (Trestolone acetate): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MENT",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MENT (Trestolone acetate): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MENT",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MENT (Trestolone acetate): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "MENT",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "metformin",
    "title": "Metformin",
    "aliases": [
      "Glucophage",
      "Glumetza"
    ],
    "category": "Metformin",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Metformin guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Metformin is simple to prescribe but easy to log badly. Cleaner meal-context and GI timing notes make dose-tolerance decisions much safer.",
    "dosingSection": {
      "overview": "With Metformin, consistency beats complexity. Hold one clean routine long enough to produce signal. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Metformin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Metformin timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Metformin appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Metformin: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Metformin&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Metformin: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Metformin",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Metformin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Metformin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Metformin: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Metformin+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Metformin",
    "subtitle": "Metformin daily routine guide with meal and GI pattern clarity.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach"
  },
  {
    "slug": "methenolone-acetate-primobolan",
    "title": "Methenolone Acetate(Primobolan)",
    "aliases": [
      "Methenolone Acetate(Primobolan)"
    ],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Methenolone Acetate(Primobolan) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Methenolone Acetate, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For Methenolone Acetate, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Methenolone Acetate and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Methenolone Acetate timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Methenolone Acetate may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Methenolone Acetate appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Methenolone Acetate(Primobolan): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Methenolone%20Acetate",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Methenolone Acetate(Primobolan): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Methenolone%20Acetate",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Methenolone Acetate(Primobolan): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Methenolone Acetate",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "methylene-blue",
    "title": "Methylene Blue",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Methylene Blue guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Methylene Blue belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For Methylene Blue, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Methylene Blue and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Methylene Blue timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Methylene Blue may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Methylene Blue appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Methylene Blue: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Methylene%20Blue",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Methylene Blue: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Methylene%20Blue",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Methylene Blue: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Methylene Blue",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "methylstenbolone",
    "title": "Methylstenbolone",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Methylstenbolone guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Methylstenbolone, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Methylstenbolone requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Methylstenbolone and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Methylstenbolone timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Methylstenbolone may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Methylstenbolone appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Methylstenbolone: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Methylstenbolone",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Methylstenbolone: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Methylstenbolone",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Methylstenbolone: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Methylstenbolone",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "metribolone",
    "title": "Metribolone",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Metribolone guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Metribolone should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Metribolone requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Metribolone and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Metribolone timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Metribolone may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Metribolone appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Metribolone: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Metribolone",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Metribolone: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Metribolone",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Metribolone: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Metribolone",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "mgf",
    "title": "MGF",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "MGF guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "MGF should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "MGF requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for MGF and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log MGF timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "MGF may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for MGF versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MGF: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MGF",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MGF: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MGF",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MGF: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "MGF",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "mic",
    "title": "MIC Injection",
    "aliases": [
      "Lipotropic Injection",
      "Lipo-B"
    ],
    "category": "Weight Loss Blend",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "MIC Injection guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "MIC blends are often treated as generic fat-loss shots. This page keeps the log specific: blend context, schedule, and realistic outcome windows.",
    "dosingSection": {
      "overview": "For MIC Injection, conservative adjustments and measured rechecks are safer than abrupt protocol jumps. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for MIC Injection and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact MIC Injection timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is MIC Injection appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MIC Injection: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:MIC%20Injection&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MIC Injection: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=MIC%20Injection",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MIC Injection: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MIC%20Injection",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "MIC Injection: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MIC%20Injection+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "MIC Injection",
    "subtitle": "MIC blend workflow guide with composition-aware tracking.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound",
        "Supportive"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "minoxidil",
    "title": "Minoxidil",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Minoxidil guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Treat Minoxidil as a consistency challenge: same routine, same markers, fewer assumptions. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Minoxidil protocols are easier to interpret when you avoid changing multiple variables at once. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Minoxidil and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Minoxidil timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Minoxidil appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Minoxidil: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Minoxidil",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Minoxidil: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Minoxidil",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Minoxidil: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Minoxidil",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach"
  },
  {
    "slug": "mk-677-ibutamoren",
    "title": "MK-677(Ibutamoren)",
    "aliases": [
      "MK-677(Ibutamoren)"
    ],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "MK-677(Ibutamoren) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "MK-677 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "MK-677 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for MK-677 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact MK-677 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "MK-677 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is MK-677 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MK-677(Ibutamoren): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MK-677",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MK-677(Ibutamoren): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MK-677",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MK-677(Ibutamoren): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "MK-677",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "molybdenum",
    "title": "Molybdenum",
    "aliases": [
      "Mo"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Molybdenum guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Molybdenum works best as a steady support protocol with measured check-ins rather than short reactive cycles. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Molybdenum decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Keep Molybdenum schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Molybdenum timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Molybdenum, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Molybdenum: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Molybdenum-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Molybdenum: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Molybdenum",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Molybdenum: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Molybdenum+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Molybdenum",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "mots-c",
    "title": "MOTS-C",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "MOTS-C guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "MOTS-c is frequently discussed in performance circles. This guide keeps expectations grounded and pushes for trend windows long enough to mean something.",
    "dosingSection": {
      "overview": "MOTS-C requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for MOTS-C and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log MOTS-C timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "MOTS-C may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for MOTS-C versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MOTS-C: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MOTS-C",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MOTS-C: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MOTS-C",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MOTS-C: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "MOTS-C",
    "subtitle": "MOTS-c metabolic-support context with realistic trend windows.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "mt-1",
    "title": "MT-1",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "MT-1 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For MT-1, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "MT-1 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for MT-1 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log MT-1 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "MT-1 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for MT-1 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MT-1: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MT-1",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MT-1: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MT-1",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MT-1: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "MT-1",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "mt-2",
    "title": "MT-2",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "MT-2 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "MT-2 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "MT-2 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for MT-2 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log MT-2 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "MT-2 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for MT-2 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MT-2: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MT-2",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MT-2: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MT-2",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MT-2: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "MT-2",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "n-acetyl-epitalon-amidate",
    "title": "N-Acetyl Epitalon Amidate",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "N-Acetyl Epitalon Amidate guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "N-Acetyl Epitalon Amidate belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For N-Acetyl Epitalon Amidate, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for N-Acetyl Epitalon Amidate and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log N-Acetyl Epitalon Amidate timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "N-Acetyl Epitalon Amidate may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for N-Acetyl Epitalon Amidate versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "N-Acetyl Epitalon Amidate: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=N-Acetyl%20Epitalon%20Amidate",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "N-Acetyl Epitalon Amidate: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=N-Acetyl%20Epitalon%20Amidate",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "N-Acetyl Epitalon Amidate: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "N-Acetyl Epitalon Amidate",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "nad-plus",
    "title": "NAD+",
    "aliases": [
      "Nicotinamide Adenine Dinucleotide",
      "NAD"
    ],
    "category": "Coenzyme",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "NAD+ guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "NAD+ experiences are highly rate-sensitive for many users. This guide helps you log administration pace and symptom response in a way that supports safer conversations.",
    "dosingSection": {
      "overview": "NAD+ decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for NAD+ and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact NAD+ timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is NAD+ appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "NAD+: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:NAD%2B&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "NAD+: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=NAD%2B",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "NAD+: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=NAD%2B",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "NAD+: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=NAD%2B+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "NAD+",
    "subtitle": "NAD+ support context with administration-rate awareness.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "nandromix-300mg",
    "title": "NANDROMIX 300mg",
    "aliases": [
      "NANDROMIX 300mg"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "NANDROMIX 300mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "NANDROMIX should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "NANDROMIX should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for NANDROMIX and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact NANDROMIX timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "NANDROMIX may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is NANDROMIX appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "NANDROMIX 300mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=NANDROMIX%20300mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "NANDROMIX 300mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=NANDROMIX%20300mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "NANDROMIX 300mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "NANDROMIX",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "npp",
    "title": "NPP",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "NPP guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For NPP, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "NPP should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for NPP and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact NPP timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "NPP may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is NPP appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "NPP: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=NPP",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "NPP: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=NPP",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "NPP: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "NPP",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "orforglipron",
    "title": "Orforglipron",
    "aliases": [
      "LY3502970"
    ],
    "category": "Experimental",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Orforglipron guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Orforglipron discussions usually fail when people treat trial headlines like finished clinical guidance. This guide keeps the focus on uncertainty, tolerability, and disciplined monitoring.",
    "dosingSection": {
      "overview": "Orforglipron requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Orforglipron so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Orforglipron dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Orforglipron may have incomplete long-term safety evidence; keep expectations conservative.",
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Orforglipron titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Orforglipron: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Orforglipron",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Orforglipron: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Orforglipron",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Orforglipron: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Orforglipron",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Orforglipron: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Orforglipron+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Orforglipron",
    "subtitle": "Oral investigational incretin profile with cautious expectation setting.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "GLP-1/GIP",
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "ostarine-mk-2866",
    "title": "Ostarine / MK-2866",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Ostarine / MK-2866 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Ostarine / MK-2866, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Ostarine / MK-2866 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Ostarine / MK-2866 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Ostarine / MK-2866 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Ostarine / MK-2866 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Ostarine / MK-2866 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Ostarine / MK-2866: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Ostarine%20%2F%20MK-2866",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Ostarine / MK-2866: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Ostarine%20%2F%20MK-2866",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Ostarine / MK-2866: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Ostarine / MK-2866",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "oxytocin-acetate",
    "title": "Oxytocin Acetate",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Oxytocin Acetate guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Oxytocin Acetate should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For Oxytocin Acetate, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Oxytocin Acetate and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Oxytocin Acetate timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Oxytocin Acetate may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Oxytocin Acetate versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Oxytocin Acetate: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Oxytocin%20Acetate",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Oxytocin Acetate: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Oxytocin%20Acetate",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Oxytocin Acetate: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Oxytocin Acetate",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Hormone",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "p21",
    "title": "P21",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "P21 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For P21, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "P21 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for P21 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log P21 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "P21 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for P21 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "P21: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=P21",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "P21: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=P21",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "P21: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "P21",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "pe-22-28",
    "title": "PE 22-28",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "PE 22-28 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "PE 22-28 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "PE 22-28 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for PE 22-28 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log PE 22-28 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "PE 22-28 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for PE 22-28 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "PE 22-28: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=PE%2022-28",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "PE 22-28: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=PE%2022-28",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "PE 22-28: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "PE 22-28",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "peg-mgf",
    "title": "PEG MGF",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "PEG MGF guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "PEG MGF belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "PEG MGF should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for PEG MGF and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log PEG MGF timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "PEG MGF may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for PEG MGF versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "PEG MGF: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=PEG%20MGF",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "PEG MGF: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=PEG%20MGF",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "PEG MGF: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "PEG MGF",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "phosphorus",
    "title": "Phosphorus",
    "aliases": [
      "P"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Phosphorus guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Phosphorus looks simple, but better results usually come from routine, timing consistency, and objective follow-up. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Phosphorus decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Keep Phosphorus schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Phosphorus timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Phosphorus, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Phosphorus: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Phosphorus-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Phosphorus: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Phosphorus",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Phosphorus: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Phosphorus+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Phosphorus",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "pinealon",
    "title": "Pinealon",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Pinealon guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Pinealon belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "Pinealon requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Pinealon and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Pinealon timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Pinealon may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Pinealon versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Pinealon: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Pinealon",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Pinealon: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Pinealon",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Pinealon: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Pinealon",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "pnc-27",
    "title": "PNC 27",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "PNC 27 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For PNC 27, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "PNC 27 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for PNC 27 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log PNC 27 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "PNC 27 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for PNC 27 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "PNC 27: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=PNC%2027",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "PNC 27: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=PNC%2027",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "PNC 27: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "PNC 27",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "potassium",
    "title": "Potassium",
    "aliases": [
      "K"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Potassium guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Potassium works best as a steady support protocol with measured check-ins rather than short reactive cycles. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Potassium should follow a steady cadence with periodic tolerance and response review. [C1]",
      "protocolPatterns": [
        "Keep Potassium schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Potassium timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Potassium, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Potassium: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Potassium-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Potassium: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Potassium",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Potassium: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Potassium+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Potassium",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "prednisone",
    "title": "Prednisone",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Prednisone guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Prednisone tracking improves fast once you define one clear objective and log against it every week. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Prednisone protocols are easier to interpret when you avoid changing multiple variables at once. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Prednisone and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Prednisone timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Prednisone appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Prednisone: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Prednisone",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Prednisone: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Prednisone",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Prednisone: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Prednisone",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach"
  },
  {
    "slug": "primobolan-e",
    "title": "Primobolan E",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Primobolan E guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Primobolan E belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Primobolan E requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Primobolan E and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Primobolan E timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Primobolan E may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Primobolan E appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Primobolan E: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Primobolan%20E",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Primobolan E: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Primobolan%20E",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Primobolan E: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Primobolan E",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "proviron",
    "title": "Proviron",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Proviron guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Proviron belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Proviron should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Proviron and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Proviron timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Proviron may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Proviron appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Proviron: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Proviron",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Proviron: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Proviron",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Proviron: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Proviron",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "pt-141",
    "title": "PT-141 (Bremelanotide)",
    "aliases": [
      "Vyleesi",
      "PT-141",
      "PT-141 (Bremelanotide)"
    ],
    "category": "Other Peptide",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "PT-141 (Bremelanotide) guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "PT-141 is typically discussed as-needed, which makes logs messy fast. This guide helps you structure timing, trigger context, and response windows.",
    "dosingSection": {
      "overview": "PT-141 protocols are easier to interpret when you avoid changing multiple variables at once. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for PT-141 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log PT-141 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for PT-141 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "PT-141 (Bremelanotide): FDA/openFDA labeling and safety records",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "PT-141 (Bremelanotide): DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=PT-141",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "PT-141 (Bremelanotide): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=PT-141",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "PT-141 (Bremelanotide): PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=PT-141+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "PT-141",
    "subtitle": "PT-141 on-demand context with timing and response structure.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "coach"
  },
  {
    "slug": "rad140",
    "title": "RAD140",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "RAD140 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "RAD140 belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "RAD140 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for RAD140 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact RAD140 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "RAD140 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is RAD140 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "RAD140: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=RAD140",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "RAD140: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=RAD140",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "RAD140: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "RAD140",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "retatrutide",
    "title": "Retatrutide",
    "aliases": [
      "LY3437943"
    ],
    "category": "Experimental",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Retatrutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Retatrutide conversation should start with uncertainty, not hype. Treat it like a high-variance investigational signal: conservative expectations, documented side effects, and zero self-directed escalation.",
    "dosingSection": {
      "overview": "Retatrutide requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Retatrutide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Retatrutide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Retatrutide may have incomplete long-term safety evidence; keep expectations conservative.",
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Retatrutide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Retatrutide: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Retatrutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Retatrutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Retatrutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Retatrutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Retatrutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Retatrutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Retatrutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Retatrutide",
    "subtitle": "Investigational triple-agonist context with strict safety framing.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "retatrutide-5mg-plus-cagrilintide-5mg-blend",
    "title": "Retatrutide 5mg+Cagrilintide 5mg Blend",
    "aliases": [
      "Retatrutide 5mg+Cagrilintide 5mg Blend"
    ],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Retatrutide 5mg+Cagrilintide 5mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Retatrutide + Cagrilintide Blend belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "Retatrutide + Cagrilintide Blend should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Retatrutide + Cagrilintide Blend so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Retatrutide + Cagrilintide Blend dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Retatrutide + Cagrilintide Blend may have incomplete long-term safety evidence; keep expectations conservative.",
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Retatrutide + Cagrilintide Blend titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Retatrutide 5mg+Cagrilintide 5mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Retatrutide%205mg%2BCagrilintide%205mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Retatrutide 5mg+Cagrilintide 5mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Retatrutide%205mg%2BCagrilintide%205mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Retatrutide 5mg+Cagrilintide 5mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Retatrutide + Cagrilintide Blend",
    "subtitle": "Retatrutide + Cagrilintide blend with component-aware tracking context.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [
      {
        "name": "Retatrutide",
        "amount": "5mg"
      },
      {
        "name": "Cagrilintide",
        "amount": "5mg"
      }
    ],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "ripex",
    "title": "RIPEX",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "RIPEX guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "RIPEX belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For RIPEX, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for RIPEX and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact RIPEX timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "RIPEX may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is RIPEX appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "RIPEX: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=RIPEX",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "RIPEX: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=RIPEX",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "RIPEX: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "RIPEX",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "rp226",
    "title": "RP226",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "RP226 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "RP226 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "RP226 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for RP226 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact RP226 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "RP226 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is RP226 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "RP226: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=RP226",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "RP226: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=RP226",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "RP226: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "RP226",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "salbutamol",
    "title": "SALBUTAMOL",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "SALBUTAMOL guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "SALBUTAMOL belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "SALBUTAMOL requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for SALBUTAMOL and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact SALBUTAMOL timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "SALBUTAMOL may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is SALBUTAMOL appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "SALBUTAMOL: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=SALBUTAMOL",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "SALBUTAMOL: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=SALBUTAMOL",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "SALBUTAMOL: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "SALBUTAMOL",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "selank",
    "title": "Selank",
    "aliases": [
      "Tuftsin Analog"
    ],
    "category": "Nootropic Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Selank guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Selank logs tend to over-index on subjective mood snapshots. This guide pushes a more useful approach: day-function markers, consistency, and timing clarity.",
    "dosingSection": {
      "overview": "Selank requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Selank and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Selank timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Selank may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Selank versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Selank: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Selank",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Selank: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Selank",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Selank: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Selank",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Selank: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Selank+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Selank",
    "subtitle": "Nootropic peptide context with day-function tracking cues.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "selank-10mg-plus-semax-10mg-blend",
    "title": "Selank 10mg + Semax 10mg Blend",
    "aliases": [
      "Selank 10mg + Semax 10mg Blend"
    ],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Selank 10mg + Semax 10mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Selank + Semax Blend should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For Selank + Semax Blend, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Treat Selank + Semax Blend as a multi-signal protocol and define what each component is expected to influence. [C2]",
        "Do not add new stacked compounds mid-cycle unless you can isolate effects clearly. [C3]"
      ],
      "monitoringWindows": [
        "Log component-related outcomes separately before making blend-level conclusions. [C2]",
        "Escalate unusual reactions quickly since blend attribution is inherently less precise. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Selank + Semax Blend timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Selank + Semax Blend may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Selank + Semax Blend versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Selank 10mg + Semax 10mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Selank%2010mg%20%2B%20Semax%2010mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Selank 10mg + Semax 10mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Selank%2010mg%20%2B%20Semax%2010mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Selank 10mg + Semax 10mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Selank + Semax Blend",
    "subtitle": "Selank + Semax blend with component-aware tracking context.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [
      {
        "name": "Selank",
        "amount": "10mg"
      },
      {
        "name": "Semax",
        "amount": "10mg"
      }
    ],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "selenium",
    "title": "Selenium",
    "aliases": [
      "Se"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Selenium guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Selenium looks simple, but better results usually come from routine, timing consistency, and objective follow-up. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Selenium should follow a steady cadence with periodic tolerance and response review. [C1]",
      "protocolPatterns": [
        "Keep Selenium schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Selenium timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Selenium, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Selenium: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Selenium-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Selenium: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Selenium",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Selenium: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Selenium+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Selenium",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "semaglutide",
    "title": "Semaglutide",
    "aliases": [
      "Ozempic",
      "Wegovy",
      "Rybelsus"
    ],
    "category": "GLP-1",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Semaglutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Semaglutide works best when the weekly rhythm is boringly consistent. This guide focuses on the real-world cadence: dose day, appetite curve, GI tolerance windows, and clean notes your clinician can act on.",
    "dosingSection": {
      "overview": "For Semaglutide, protocol moves are safer when escalation is tied to documented tolerance windows. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Semaglutide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Semaglutide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Semaglutide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Semaglutide: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Semaglutide&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Semaglutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Semaglutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Semaglutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Semaglutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Semaglutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Semaglutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Semaglutide",
    "subtitle": "Weekly GLP-1 anchor protocol with appetite and GI trend tracking.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "clinical"
  },
  {
    "slug": "semax",
    "title": "Semax",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Semax guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Semax discussions improve when cognitive claims are tied to repeatable tasks and routine windows, not one-off impressions.",
    "dosingSection": {
      "overview": "Semax requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Semax and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Semax timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Semax may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Semax versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Semax: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Semax",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Semax: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Semax",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Semax: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Semax",
    "subtitle": "Semax cognitive-support tracking guide with structured notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "sermorelin",
    "title": "Sermorelin",
    "aliases": [
      "GHRH 1-29",
      "Sermorelin Acetate"
    ],
    "category": "GH Secretagogue",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Sermorelin guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Sermorelin outcomes are hard to read without consistent nighttime routine context. This page helps keep sleep, timing, and next-day markers aligned.",
    "dosingSection": {
      "overview": "Sermorelin requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Sermorelin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Sermorelin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Sermorelin may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Sermorelin versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Sermorelin: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Sermorelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Sermorelin: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Sermorelin",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Sermorelin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Sermorelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Sermorelin: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Sermorelin+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Sermorelin",
    "subtitle": "Sermorelin practical tracking guide for nightly protocol routines.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "shb",
    "title": "SHB",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "SHB guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "SHB should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "SHB should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for SHB and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact SHB timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "SHB may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is SHB appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "SHB: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=SHB",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "SHB: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=SHB",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "SHB: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "SHB",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "shr",
    "title": "SHR",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "SHR guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "SHR belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "SHR should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for SHR and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact SHR timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "SHR may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is SHR appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "SHR: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=SHR",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "SHR: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=SHR",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "SHR: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "SHR",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "sildenafil-viagra",
    "title": "Sildenafil(Viagra)",
    "aliases": [
      "Sildenafil(Viagra)"
    ],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Sildenafil(Viagra) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Sildenafil tracking improves fast once you define one clear objective and log against it every week. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Sildenafil protocols are easier to interpret when you avoid changing multiple variables at once. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Sildenafil and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Sildenafil timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Sildenafil appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Sildenafil(Viagra): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Sildenafil",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Sildenafil(Viagra): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Sildenafil",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Sildenafil(Viagra): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Sildenafil",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach"
  },
  {
    "slug": "slu-pp-332",
    "title": "SLU-PP-332",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "SLU-PP-332 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "SLU-PP-332 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "SLU-PP-332 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for SLU-PP-332 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact SLU-PP-332 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "SLU-PP-332 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is SLU-PP-332 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "SLU-PP-332: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=SLU-PP-332",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "SLU-PP-332: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=SLU-PP-332",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "SLU-PP-332: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "SLU-PP-332",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "slupp-332-250mcg-plus-bam15-50mcg",
    "title": "slupp-332 250mcg+BAM15 50mcg",
    "aliases": [
      "slupp-332 250mcg+BAM15 50mcg"
    ],
    "category": "Compound Blend",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "slupp-332 250mcg+BAM15 50mcg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Slupp 332 + Bam15 Blend, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For Slupp 332 + Bam15 Blend, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Treat Slupp 332 + Bam15 Blend as a multi-signal protocol and define what each component is expected to influence. [C2]",
        "Do not add new stacked compounds mid-cycle unless you can isolate effects clearly. [C3]"
      ],
      "monitoringWindows": [
        "Log component-related outcomes separately before making blend-level conclusions. [C2]",
        "Escalate unusual reactions quickly since blend attribution is inherently less precise. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Slupp 332 + Bam15 Blend timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Slupp 332 + Bam15 Blend may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Slupp 332 + Bam15 Blend appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "slupp-332 250mcg+BAM15 50mcg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=slupp-332%20250mcg%2BBAM15%2050mcg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "slupp-332 250mcg+BAM15 50mcg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=slupp-332%20250mcg%2BBAM15%2050mcg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "slupp-332 250mcg+BAM15 50mcg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Slupp 332 + Bam15 Blend",
    "subtitle": "Slupp 332 + Bam15 blend with component-aware tracking context.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [
      {
        "name": "Slupp 332",
        "amount": "250mcg"
      },
      {
        "name": "Bam15",
        "amount": "50mcg"
      }
    ],
    "taxonomy": {
      "classTags": [
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "snap-8",
    "title": "SNAP-8",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "SNAP-8 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "SNAP-8 belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "SNAP-8 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for SNAP-8 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log SNAP-8 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "SNAP-8 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for SNAP-8 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "SNAP-8: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=SNAP-8",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "SNAP-8: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=SNAP-8",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "SNAP-8: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "SNAP-8",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "sodium",
    "title": "Sodium",
    "aliases": [
      "Na"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Sodium guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Sodium tracking is most useful when you link dose timing, tolerance, and symptom context in one log entry. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "For Sodium, conservative adjustments and measured rechecks are safer than abrupt protocol jumps. [C1]",
      "protocolPatterns": [
        "Keep Sodium schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Sodium timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Sodium, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Sodium: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/list-all/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Sodium: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Sodium",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Sodium: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Sodium+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Sodium",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "sr9009",
    "title": "SR9009",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "SR9009 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "SR9009 belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For SR9009, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for SR9009 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact SR9009 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "SR9009 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is SR9009 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "SR9009: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=SR9009",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "SR9009: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=SR9009",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "SR9009: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "SR9009",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "ss-31",
    "title": "SS-31",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "SS-31 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "SS-31 belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "SS-31 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for SS-31 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log SS-31 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "SS-31 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for SS-31 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "SS-31: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=SS-31",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "SS-31: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=SS-31",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "SS-31: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "SS-31",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "stanozolol-oil-base-winstrol",
    "title": "STANOZOLOL(Oil base)winstrol",
    "aliases": [
      "STANOZOLOL(Water)winstrol",
      "STANOZOLOL(Oil base)winstrol"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "STANOZOLOL(Oil base)winstrol guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "STANOZOLOL winstrol belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "STANOZOLOL winstrol should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for STANOZOLOL winstrol and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact STANOZOLOL winstrol timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "STANOZOLOL winstrol may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is STANOZOLOL winstrol appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "STANOZOLOL(Oil base)winstrol: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=STANOZOLOLwinstrol",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "STANOZOLOL(Oil base)winstrol: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=STANOZOLOLwinstrol",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "STANOZOLOL(Oil base)winstrol: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "STANOZOLOL winstrol",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "superdrol",
    "title": "Superdrol",
    "aliases": [
      "Superdrol(Methyldrostanolone)"
    ],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Superdrol guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Superdrol, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For Superdrol, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Superdrol and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Superdrol timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Superdrol may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Superdrol appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Superdrol: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Superdrol",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Superdrol: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Superdrol",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Superdrol: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Superdrol",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "supertest-450mg",
    "title": "Supertest 450mg",
    "aliases": [
      "Supertest 450mg"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Supertest 450mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Supertest should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Supertest requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Supertest and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Supertest timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Supertest may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Supertest appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Supertest 450mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Supertest%20450mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Supertest 450mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Supertest%20450mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Supertest 450mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Supertest",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "survodutide",
    "title": "Survodutide",
    "aliases": [
      "BI 456906"
    ],
    "category": "Experimental",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Survodutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Survodutide should be handled like a high-uncertainty candidate. The right posture is conservative assumptions, explicit stop rules, and source-backed review.",
    "dosingSection": {
      "overview": "Survodutide should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Survodutide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Survodutide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Survodutide may have incomplete long-term safety evidence; keep expectations conservative.",
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Survodutide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Survodutide: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Survodutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Survodutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Survodutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Survodutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Survodutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Survodutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Survodutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Survodutide",
    "subtitle": "Investigational metabolic therapy with strong caution posture.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "sustanon-250mg",
    "title": "Sustanon 250mg",
    "aliases": [
      "Sustanon 250mg"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Sustanon 250mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Sustanon belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Sustanon should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Sustanon and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Sustanon timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Sustanon may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Sustanon appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Sustanon 250mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Sustanon%20250mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Sustanon 250mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Sustanon%20250mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Sustanon 250mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Sustanon",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "sustanon-400mg",
    "title": "Sustanon 400mg",
    "aliases": [
      "Sustanon 400mg"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Sustanon 400mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Sustanon belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Sustanon should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Sustanon and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Sustanon timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Sustanon may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Sustanon appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Sustanon 400mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Sustanon%20400mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Sustanon 400mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Sustanon%20400mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Sustanon 400mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Sustanon",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "t3",
    "title": "T3",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "T3 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "T3 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For T3, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for T3 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact T3 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "T3 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is T3 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "T3: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=T3",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "T3: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=T3",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "T3: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "T3",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Hormone",
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "t4",
    "title": "T4",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "T4 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "T4 belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "T4 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for T4 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact T4 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "T4 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is T4 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "T4: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=T4",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "T4: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=T4",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "T4: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "T4",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Hormone",
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "tadalafil-cialis",
    "title": "Tadalafil(Cialis)",
    "aliases": [
      "Tadalafil(Cialis)"
    ],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Tadalafil(Cialis) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Treat Tadalafil as a consistency challenge: same routine, same markers, fewer assumptions. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Tadalafil protocols are easier to interpret when you avoid changing multiple variables at once. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Tadalafil and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Tadalafil timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Tadalafil appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tadalafil(Cialis): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tadalafil",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tadalafil(Cialis): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tadalafil",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tadalafil(Cialis): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Tadalafil",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach"
  },
  {
    "slug": "tamoxifen-nolvadex",
    "title": "Tamoxifen(Nolvadex)",
    "aliases": [
      "Tamoxifen(Nolvadex)"
    ],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Tamoxifen(Nolvadex) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Treat Tamoxifen as a consistency challenge: same routine, same markers, fewer assumptions. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "With Tamoxifen, consistency beats complexity. Hold one clean routine long enough to produce signal. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Tamoxifen and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Tamoxifen timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Tamoxifen appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tamoxifen(Nolvadex): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tamoxifen",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tamoxifen(Nolvadex): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tamoxifen",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tamoxifen(Nolvadex): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Tamoxifen",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach"
  },
  {
    "slug": "tb-500",
    "title": "TB-500 (Thymosin Beta-4)",
    "aliases": [
      "Thymosin Beta-4",
      "TB-500(TB4)",
      "TB-500 (Thymosin Beta-4)"
    ],
    "category": "Healing Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TB-500 (Thymosin Beta-4) guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "TB-500 is often discussed in loading and maintenance phases. If you do not segment your log by phase, you cannot tell what changed or why.",
    "dosingSection": {
      "overview": "For TB-500, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for TB-500 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log TB-500 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "TB-500 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for TB-500 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TB-500 (Thymosin Beta-4): Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=TB-500",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TB-500 (Thymosin Beta-4): DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=TB-500",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TB-500 (Thymosin Beta-4): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TB-500",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "TB-500 (Thymosin Beta-4): PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TB-500+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "TB-500",
    "subtitle": "TB-500 recovery-cycle guide with phase-based monitoring.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "tb-500-frag",
    "title": "TB-500 FRAG",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TB-500 FRAG guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For TB-500 FRAG, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "TB-500 FRAG requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for TB-500 FRAG and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log TB-500 FRAG timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "TB-500 FRAG may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for TB-500 FRAG versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TB-500 FRAG: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TB-500%20FRAG",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TB-500 FRAG: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TB-500%20FRAG",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TB-500 FRAG: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "TB-500 FRAG",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "telmisartan",
    "title": "Telmisartan",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Telmisartan guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Treat Telmisartan as a consistency challenge: same routine, same markers, fewer assumptions. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Telmisartan protocols are easier to interpret when you avoid changing multiple variables at once. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Telmisartan and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Telmisartan timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Telmisartan appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Telmisartan: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Telmisartan",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Telmisartan: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Telmisartan",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Telmisartan: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Telmisartan",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach"
  },
  {
    "slug": "tesamorelin",
    "title": "Tesamorelin",
    "aliases": [
      "Egrifta"
    ],
    "category": "GH Secretagogue",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Tesamorelin guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Tesamorelin is one of the few entries here with clearer clinical pathway context. Still, better outcomes come from indication-aware logging and disciplined follow-up.",
    "dosingSection": {
      "overview": "Tesamorelin protocols are easier to interpret when you avoid changing multiple variables at once. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Tesamorelin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Tesamorelin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Tesamorelin versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tesamorelin: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Tesamorelin&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tesamorelin: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tesamorelin",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tesamorelin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tesamorelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Tesamorelin: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tesamorelin+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Tesamorelin",
    "subtitle": "Tesamorelin guide with indication-aware safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "coach"
  },
  {
    "slug": "tesamorelin-11mg-plus-ipamorelin-6mg-blend",
    "title": "Tesamorelin 11mg + Ipamorelin 6mg Blend",
    "aliases": [
      "Tesamorelin 11mg + Ipamorelin 6mg Blend"
    ],
    "category": "Research Peptide",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Tesamorelin 11mg + Ipamorelin 6mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Tesamorelin + Ipamorelin Blend is easier to judge when your notes read like a timeline instead of scattered snapshots. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For Tesamorelin + Ipamorelin Blend, stable cadence is the foundation for any useful adjustment discussion. [C1]",
      "protocolPatterns": [
        "Treat Tesamorelin + Ipamorelin Blend as a multi-signal protocol and define what each component is expected to influence. [C2]",
        "Do not add new stacked compounds mid-cycle unless you can isolate effects clearly. [C3]"
      ],
      "monitoringWindows": [
        "Log component-related outcomes separately before making blend-level conclusions. [C2]",
        "Escalate unusual reactions quickly since blend attribution is inherently less precise. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Tesamorelin + Ipamorelin Blend timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Tesamorelin + Ipamorelin Blend versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tesamorelin 11mg + Ipamorelin 6mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tesamorelin%2011mg%20%2B%20Ipamorelin%206mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tesamorelin 11mg + Ipamorelin 6mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tesamorelin%2011mg%20%2B%20Ipamorelin%206mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tesamorelin 11mg + Ipamorelin 6mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Tesamorelin + Ipamorelin Blend",
    "subtitle": "Tesamorelin + Ipamorelin blend with component-aware tracking context.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [
      {
        "name": "Tesamorelin",
        "amount": "11mg"
      },
      {
        "name": "Ipamorelin",
        "amount": "6mg"
      }
    ],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "coach"
  },
  {
    "slug": "tesofensine",
    "title": "Tesofensine",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Tesofensine guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Tesofensine discussions can drift into expectation-heavy narratives. This guide emphasizes appetite, sleep, and tolerability tracking with clean temporal context.",
    "dosingSection": {
      "overview": "For Tesofensine, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Tesofensine and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Tesofensine timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Tesofensine may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Tesofensine appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tesofensine: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tesofensine",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tesofensine: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tesofensine",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tesofensine: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Tesofensine",
    "subtitle": "Tesofensine oral context with appetite and side-effect structure.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "test-base-no-ester",
    "title": "TEST BASE (NO Ester)",
    "aliases": [
      "TEST BASE (NO Ester)"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TEST BASE (NO Ester) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For TEST BASE, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "TEST BASE should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for TEST BASE and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact TEST BASE timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "TEST BASE may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TEST BASE appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TEST BASE (NO Ester): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TEST%20BASE",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TEST BASE (NO Ester): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TEST%20BASE",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TEST BASE (NO Ester): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "TEST BASE",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "test-cypionate",
    "title": "TEST CYPIONATE",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TEST CYPIONATE guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "TEST CYPIONATE should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For TEST CYPIONATE, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for TEST CYPIONATE and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact TEST CYPIONATE timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "TEST CYPIONATE may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TEST CYPIONATE appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TEST CYPIONATE: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TEST%20CYPIONATE",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TEST CYPIONATE: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TEST%20CYPIONATE",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TEST CYPIONATE: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "TEST CYPIONATE",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "test-enanthate",
    "title": "TEST ENANTHATE",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TEST ENANTHATE guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "TEST ENANTHATE belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For TEST ENANTHATE, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for TEST ENANTHATE and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact TEST ENANTHATE timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "TEST ENANTHATE may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TEST ENANTHATE appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TEST ENANTHATE: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TEST%20ENANTHATE",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TEST ENANTHATE: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TEST%20ENANTHATE",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TEST ENANTHATE: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "TEST ENANTHATE",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "test-p",
    "title": "TEST P",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TEST P guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "TEST P should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "TEST P requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for TEST P and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact TEST P timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "TEST P may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TEST P appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TEST P: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TEST%20P",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TEST P: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TEST%20P",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TEST P: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "TEST P",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "test-suspension-100mg",
    "title": "TEST SUSPENSION 100mg",
    "aliases": [
      "TEST SUSPENSION 100mg"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TEST SUSPENSION 100mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "TEST SUSPENSION belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "TEST SUSPENSION requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for TEST SUSPENSION and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact TEST SUSPENSION timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "TEST SUSPENSION may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TEST SUSPENSION appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TEST SUSPENSION 100mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TEST%20SUSPENSION%20100mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TEST SUSPENSION 100mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TEST%20SUSPENSION%20100mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TEST SUSPENSION 100mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "TEST SUSPENSION",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "test-undecanoate-300",
    "title": "TEST Undecanoate 300",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TEST Undecanoate 300 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For TEST Undecanoate 300, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "TEST Undecanoate 300 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for TEST Undecanoate 300 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact TEST Undecanoate 300 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "TEST Undecanoate 300 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TEST Undecanoate 300 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TEST Undecanoate 300: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TEST%20Undecanoate%20300",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TEST Undecanoate 300: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TEST%20Undecanoate%20300",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TEST Undecanoate 300: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "TEST Undecanoate 300",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "testo-600mg",
    "title": "Testo 600mg",
    "aliases": [
      "Testo 600mg"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Testo 600mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Testo, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Testo should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Testo and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Testo timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Testo may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Testo appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Testo 600mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Testo%20600mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Testo 600mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Testo%20600mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Testo 600mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Testo",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "thymosin-alpha-1",
    "title": "Thymosin Alpha-1",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Thymosin Alpha-1 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Thymosin Alpha-1 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For Thymosin Alpha-1, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Thymosin Alpha-1 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Thymosin Alpha-1 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Thymosin Alpha-1 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Thymosin Alpha-1 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Thymosin Alpha-1: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Thymosin%20Alpha-1",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Thymosin Alpha-1: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Thymosin%20Alpha-1",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Thymosin Alpha-1: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Thymosin Alpha-1",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "thymulin",
    "title": "Thymulin",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Thymulin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Thymulin should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "Thymulin should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Thymulin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Thymulin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Thymulin may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Thymulin versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Thymulin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Thymulin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Thymulin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Thymulin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Thymulin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Thymulin",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "tirzepatide",
    "title": "Tirzepatide",
    "aliases": [
      "Mounjaro",
      "Zepbound"
    ],
    "category": "GIP/GLP-1",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Tirzepatide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Tirzepatide has a bigger response range than most people expect. The difference between noise and clarity is how you log week-to-week appetite return, GI tolerance, and energy shifts around each escalation step.",
    "dosingSection": {
      "overview": "Tirzepatide should be reviewed over structured intervals, not single difficult days. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Tirzepatide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Tirzepatide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Tirzepatide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tirzepatide: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Tirzepatide&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tirzepatide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tirzepatide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tirzepatide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tirzepatide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Tirzepatide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tirzepatide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Tirzepatide",
    "subtitle": "Dual GIP/GLP-1 weekly protocol with phase-aware response tracking.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "clinical"
  },
  {
    "slug": "tren-a",
    "title": "Tren A",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Tren A guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Tren A belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Tren A should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Tren A and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Tren A timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Tren A may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Tren A appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tren A: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tren%20A",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tren A: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tren%20A",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tren A: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Tren A",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "tren-base",
    "title": "Tren BASE",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Tren BASE guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Tren BASE belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Tren BASE should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Tren BASE and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Tren BASE timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Tren BASE may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Tren BASE appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tren BASE: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tren%20BASE",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tren BASE: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tren%20BASE",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tren BASE: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Tren BASE",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "tren-e",
    "title": "Tren E",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Tren E guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Tren E should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For Tren E, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Tren E and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Tren E timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Tren E may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Tren E appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tren E: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tren%20E",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tren E: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tren%20E",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tren E: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Tren E",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "tren-hex",
    "title": "Tren Hex",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Tren Hex guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Tren Hex should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Tren Hex should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Tren Hex and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Tren Hex timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Tren Hex may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Tren Hex appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tren Hex: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tren%20Hex",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tren Hex: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tren%20Hex",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tren Hex: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Tren Hex",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "trenmix-200mg",
    "title": "TRENMIX 200mg",
    "aliases": [
      "TRENMIX 200mg"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TRENMIX 200mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "TRENMIX should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "TRENMIX should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for TRENMIX and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact TRENMIX timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "TRENMIX may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TRENMIX appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TRENMIX 200mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TRENMIX%20200mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TRENMIX 200mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TRENMIX%20200mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TRENMIX 200mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "TRENMIX",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "tritren-225mg",
    "title": "TriTren 225mg",
    "aliases": [
      "TriTren 225mg"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TriTren 225mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "TriTren should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For TriTren, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for TriTren and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact TriTren timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "TriTren may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TriTren appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TriTren 225mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TriTren%20225mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TriTren 225mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TriTren%20225mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TriTren 225mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "TriTren",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "turinabol",
    "title": "Turinabol",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Turinabol guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Turinabol belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For Turinabol, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Turinabol and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Turinabol timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Turinabol may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Turinabol appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Turinabol: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Turinabol",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Turinabol: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Turinabol",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Turinabol: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Turinabol",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "vilon",
    "title": "Vilon",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Vilon guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Vilon belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For Vilon, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Vilon and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Vilon timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Vilon may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Vilon versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Vilon: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Vilon",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Vilon: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Vilon",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Vilon: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Vilon",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "vip",
    "title": "VIP",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "VIP guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "VIP should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "VIP should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for VIP and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Log VIP timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "VIP may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for VIP versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "VIP: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=VIP",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "VIP: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=VIP",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "VIP: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "VIP",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "vitamin-d3",
    "title": "Vitamin D3",
    "aliases": [
      "Cholecalciferol"
    ],
    "category": "Vitamin",
    "status": "nutrient",
    "statusLabel": "Nutrient Support",
    "metaDescription": "Vitamin D3 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Vitamin D3 looks simple, but good decisions are lab-driven. This guide favors measured recheck intervals over long blind supplementation runs.",
    "dosingSection": {
      "overview": "Vitamin D3 should follow a steady cadence with periodic tolerance and response review. [C1]",
      "protocolPatterns": [
        "Keep Vitamin D3 schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Vitamin D3 timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Vitamin D3, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Vitamin D3: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Vitamin%20D3&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Vitamin D3: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Vitamin%20D3",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Vitamin D3: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Vitamin%20D3",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Vitamin D3: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Vitamin%20D3+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Vitamin D3",
    "subtitle": "Vitamin D3 guide with lab-first supplementation strategy.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Vitamin",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  },
  {
    "slug": "winstrol-stanozolol",
    "title": "Winstrol(Stanozolol )",
    "aliases": [
      "Winstrol(Stanozolol )"
    ],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Winstrol(Stanozolol ) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Winstrol, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For Winstrol, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Winstrol and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Winstrol timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Winstrol may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Winstrol appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Winstrol(Stanozolol ): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Winstrol",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Winstrol(Stanozolol ): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Winstrol",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Winstrol(Stanozolol ): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Winstrol",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "yk11",
    "title": "YK11",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "YK11 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "YK11 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For YK11, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for YK11 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact YK11 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "YK11 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is YK11 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "YK11: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=YK11",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "YK11: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=YK11",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "YK11: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "YK11",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution"
  },
  {
    "slug": "zinc",
    "title": "Zinc",
    "aliases": [
      "Zn"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Zinc guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Zinc tracking is most useful when you link dose timing, tolerance, and symptom context in one log entry. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "For Zinc, conservative adjustments and measured rechecks are safer than abrupt protocol jumps. [C1]",
      "protocolPatterns": [
        "Keep Zinc schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Zinc timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Zinc, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Zinc: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Zinc: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Zinc",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Zinc: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Zinc+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Zinc",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support"
  }
]
